

## Review Article

# The role of the microbiome in gastrointestinal inflammation

David J. Sanders<sup>1</sup>, Saskia Inniss<sup>1</sup>, Gregory Sebepos-Rogers<sup>1</sup>, Farooq Z. Rahman<sup>2</sup> and  Andrew M. Smith<sup>1</sup>

<sup>1</sup>Department of Microbial Diseases, UCL Eastman Dental Institute, Royal Free Campus, University College London, London, United Kingdom; <sup>2</sup>Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, United Kingdom

**Correspondence:** Andrew M. Smith (andrew.m.smith@ucl.ac.uk)



The microbiome plays an important role in maintaining human health. Despite multiple factors being attributed to the shaping of the human microbiome, extrinsic factors such as diet and use of medications including antibiotics appear to dominate. Mucosal surfaces, particularly in the gut, are highly adapted to be able to tolerate a large population of microorganisms whilst still being able to produce a rapid and effective immune response against infection. The intestinal microbiome is not functionally independent from the host mucosa and can, through presentation of microbe-associated molecular patterns (MAMPs) and generation of microbe-derived metabolites, fundamentally influence mucosal barrier integrity and modulate host immunity. In a healthy gut there is an abundance of beneficial bacteria that help to preserve intestinal homeostasis, promote protective immune responses, and limit excessive inflammation. The importance of the microbiome is further highlighted during dysbiosis where a loss of this finely balanced microbial population can lead to mucosal barrier dysfunction, aberrant immune responses, and chronic inflammation that increases the risk of disease development. Improvements in our understanding of the microbiome are providing opportunities to harness members of a healthy microbiota to help reverse dysbiosis, reduce inflammation, and ultimately prevent disease progression.

## Introduction

The human body is inhabited by a highly diverse population of microorganisms (microbiota) that has co-evolved with their human hosts over many millennia [1]. The human microbiome, a term more precisely used to describe the genomes of these microorganisms [2], is predominantly made up of bacteria [3], however archaea, viruses, and single-cell eukaryotes (e.g. fungi and protists) are also present [4–7]. These microorganisms are at least as abundant as the number of human host cells [3,8] and combined contain far more genes than the entire human genome [9]. Over the past few decades, research related to the microbiome has intensified, facilitated by rapid advances in culture-independent, high-throughput genomic and metabolomic techniques [10–12]. Consequently, a greater understanding of microbiota population composition and host–microbe interactions has been achieved, especially in the context of human health and disease [11,13,14]. Whereas a balanced microbiota has been shown to play an important role in the maintenance of human health, impairment or imbalance in the makeup of the human microbiota (dysbiosis) can disrupt homeostasis and lead to the onset or exacerbation of human disease [15]. Multiple factors are known to influence the microbiota, however, studies have shown that the microbiome is more strongly influenced by an individual's environment [16,17]. There are significant similarities in microbiota composition of genetically unrelated individuals who share a household, with approximately 20% of interperson microbiota variability associated with environmental factors such as diet, lifestyle, and medication [16].

The human microbiome can be separated into compartment-specific ecosystems that exist on the skin and along mucosal surfaces such as those of the oral cavity, gastrointestinal tract, lungs, and genitourinary


Received: 31 March 2021

Revised: 27 May 2021

Accepted: 02 June 2021

Accepted Manuscript online:  
02 June 2021

Version of Record published:  
11 June 2021



**Figure 1.** Factors that contribute to the shaping of the human microbiome

system [1]. The largest concentration and diversity of microbiota can be found within the gut especially in the colon [1]. The mucosa, which consists of a single cell thick epithelium overlaying a layer of connective tissue called the lamina propria, provides the interface between the host and the environment and is equipped with specialised features, particularly along its apical surface, to allow physiological function whilst also being in contact with the microbiota [18]. The microbiota is however not functionally independent from the host mucosa and can fundamentally influence mucosal integrity, modulating host immune responses and mucosal inflammation.

Here we review the relationship between the microbiota and the mucosa, especially in relation to gut homeostasis and mucosal inflammation. We first discuss factors that shape an individual's microbiome and the impact the microbiome has on the intestinal mucosa during homeostasis. We then explore how dysbiosis of the microbiome can lead to mucosal inflammation, resulting in the development of human disease, and highlight current and emerging therapies being used to suppress mucosal inflammation through targeting of the microbiome.

## Factors shaping the microbiome

There is increasing evidence to suggest that there is a core microbiome shared between all individuals [19]. However, the composition and diversity of much of the gut microbiome varies greatly from person to person, adapting to both intrinsic and environmental factors [20,21]. Research to date has shown that environmental factors, mainly diet and medication, dominate over intrinsic factors, such as host genetics, in shaping the microbiome [16,22]. Age [23,24], geography [25], and birthing practices [26,27] are also known to be particularly important for determining microbiome composition (Figure 1).

### Diet

In the first year of life, the gut microbiome is relatively unstable becoming progressively more stable following weaning, taking on an adult form typically around 3 years of age [28]. Infant feeding practices as well as adult habitual diet play an important role in shaping the gut microbiome [29]. Studies looking into the effect of diet on the make-up of the intestinal microbiota have to date mainly focused on the so-called 'Western' diet, which is characterised by

high levels of fat, sugar and refined protein [30,31], and diets that are high in fibre and low in red meat, such as the Mediterranean diet [24,32].

Differences in gut microbiome composition prior to weaning have been observed between breastfed and formula-fed infants. Breastfed infants have a microbiome dominated by Lactobacilli and *Prevotella*, whereas formula-fed infants exhibit a more diverse microbial population, dominated by Enterococci, Enterobacteria, Bacteroides, Clostridia, and Streptococci [33,34]. Breastmilk contains oligosaccharides which promote the growth of beneficial *Bifidobacteria* [35]. Bifidobacteria play a major role in the fermentation and conversion of oligosaccharides into short-chain fatty acids (SCFAs), such as butyrate and propionate, which promote healthy immune function (reviewed in detail below 'The microbiome and intestinal homeostasis') [36]. In addition to providing critical nutrients and bioactive compounds, human breast milk also plays an important role in the seeding of an infant's gut microbiome, containing a variety of beneficial bacteria, including Lactobacilli and Bifidobacteria [37]. After weaning, the microbiota becomes more diverse and is dominated by Bacteroidetes and Firmicutes [38].

Studies looking at the adult gut microbiome have found that individuals consuming a Western diet experience a decrease in the total number of gut bacteria, particularly Bifidobacteria and Eubacteria, and an increase in pro-inflammatory bacteria-derived compounds [39–41]. A key aspect of the Western diet is a high intake of saturated fatty acids which has been linked to both a decrease in Gram-negative bacteria within the gut, particularly Bacteroidetes, and an increase in Lactococci [42,43]. Whilst there is currently a lack of consensus as to the precise effect of these dietary components on the microbiome, most studies have observed an overall decrease in bacterial diversity, a decrease in SCFA production, and an increase in harmful bacterial strains, such as pathogenic *Escherichia coli* (*E. coli*) [44,45]. In contrast with a Western diet, adults who consume a Mediterranean diet exhibit increased levels of Bifidobacteria, Lactobacilli, Eubacteria, and Bacteroides [46,47]. Furthermore, individuals who consume a Mediterranean diet have been shown to have increased levels of SCFA-producing bacteria, such as *Prevotella* [48]. In addition to habitual diet, research has shown that dietary diversity, meal timing as well as short- and long-term dietary modifications can change the composition and activity of the adult gut microbiome [49–52]. Caloric restriction, for example, which is a nutritional intervention of reduced energy intake, has a strong influence on the gut microbiota [53,54]. It has been found that caloric restriction can slow down age-related decline in the microbiome, increase both microbial diversity and Bacteroidetes/Firmicutes ratio, as well as change host microbial co-metabolites leading to a decrease in host lipid biosynthesis and an increase in fatty acid catabolism [55,56].

## Antibiotics and drugs

Antibiotics are medicines used in the treatment of bacterial infections. Whilst they have proved to be an effective treatment against many bacterial diseases, their antimicrobial action profoundly affects the composition and function of the gut microbiome, causing dysbiosis by killing both pathological and beneficial bacteria, and allowing the expansion of resistant microbes [57]. The effects of antibiotics on the gut microbiome are potentially long-lasting, and their use in early life has been associated with an increased risk of developing several conditions including inflammatory bowel disease (IBD) and asthma [58,59].

Antibiotics can drastically reduce, or even fully eliminate, beneficial anaerobic bacterial species such as Bifidobacteria, Lactobacilli, Bacteroides, and Clostridia [60]. After only 7 days of antibiotic treatment, microbial diversity has been found to decrease by 25%, with core phylogenetic microbiota reducing from 29 to 12 taxa and antibiotic-resistant Bacteroidetes increasing 2.5-fold [61]. Consequently, antibiotic use can also result in reduced SCFA production [62]. The effects of antibiotics on the microbiome are however dependent on the type of antibiotic used. Clindamycin, which is a broad-spectrum antibiotic, can cause microbial changes that last for up to 2 years with no recovery in Bacteroides diversity [63]. Clarithromycin and Ciprofloxacin, which are used against *Helicobacter pylori*, are associated with a decrease in Actinobacteria and Ruminococci, respectively [64,65]. Vancomycin, which is used against *Clostridium difficile* (*C. difficile*), causes an increase in Proteobacteria species and a decrease in Bacteroidetes, Ruminococci and Faecalibacteria levels, which can lead to both recurrent *C. difficile* infection (rCDI) and the growth of unwanted bacterial species, such as pathogenic *E. coli* [66,67].

Non-antibiotic drugs are also known to influence the composition and stability of the microbiome. A recent meta-analysis revealed that in addition to antibiotics, proton pump inhibitors (PPIs), metformin, and laxatives exhibit the greatest effects on gut microbiome composition and function [68]. PPIs reduce microbial diversity and cause taxonomical changes in the gut. Metformin significantly increases *E. coli* abundance and effects the number of SCFA-producing bacteria [68,69].

## Birth mode of delivery

Studies have shown that whereas vaginally delivered babies have a microbiome dominated by Lactobacilli and Prevotella, babies born by caesarean section (C-section) carry a microbiome dominated by Streptococci, Corynebacteria, and Propionibacteria [70,71]. Furthermore, babies born by C-section have been shown to have an abundance of potentially pro-inflammatory *Klebsiella* and *Enterococcus* bacteria [26]. A recent study reported that the abundance of *Klebsiella* and *Enterococcus* species in C-section born children at 1 week of life was associated with an increased number of respiratory infections over the first year [26]. Additionally, babies delivered by C-section have been shown to have lower total gut microbial diversity, delayed Bacteroidetes colonisation, and a subsequent immune system imbalance during the first 2 years of life which may result in the development of allergies [72,73].

## Age

Many studies have observed age-related changes to the gut microbiome. In infancy, the developing gut microbiome undergoes three distinct phases of progression: a developmental phase (months 3–14), a transitional phase (months 15–30), and a stable phase (months 31–46) [74]. Children and young adults have a higher abundance of Bifidobacteria and Clostridia, and a lower microbial diversity compared with adults [75]. In general, healthy adults exhibit high levels of Bacteroidetes and Firmicutes, and low levels of Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia [20,76,77]. Throughout life, intestinal levels of Firmicutes decrease whilst Bacteroidetes levels increase. Elderly people have a gut microbiome enriched with Bacteroidetes and Proteobacteria and depleted levels of Bifidobacteria and Lactobacilli [24,78]. The transition from healthy adult to healthy old age is characterised by a decrease in microbial diversity, as well as an accumulation of potentially pro-inflammatory microbes and decrease in beneficial microbes [79].

## Development geography

To date, most studies investigating the link between the microbiome and geography have focused on differences in microbiome composition amongst three contrasting human populations: hunter gatherers, traditional farming or fishing communities, and Western industrialised communities [80–84]. When comparing the microbiomes of hunter gatherers with those of more developed communities, hunter gatherers were found to have a higher microbial diversity, with enrichment of Prevotella, Treponema, and Bacteroidetes [80,81]. In contrast, Western industrialised communities have higher levels of Bacteroides and Firmicutes, with an overall lower microbial diversity. Some studies suggest that the microbiomes of traditional farming and fishing communities exhibit an intermediate state between hunter gatherers and Western industrialised communities [82,85]. Factors thought to influence gut microbiome composition amongst hunter gatherers include a diet consisting of predominately starchy foods, limited access to modern medicine, and exposure to a wide variety of pathogens and parasites [82,83]. Traditional farming or fishing communities are thought to possess microbiomes with a relatively high taxonomic diversity, allowing the host to withstand pathogens and parasites, as well as to be able to respond to dietary fluctuations due to crop seasonality [83]. In Western industrialised societies, the gut microbiome is thought to be largely determined by diets high in refined protein and fat, good sanitation and hygiene practices, and the habitual use of antibiotics and other medications [80,81,84]. Some studies have also proposed that the lower microbiome diversity found in Western industrialised communities can be attributed to an overall loss of biodiversity due to industrialisation, pollution, and use of chemicals [86,87]. Furthermore, differences in sanitised drinking water may also have an effect on the composition of the gut microbiome [88,89].

## The microbiome and intestinal homeostasis

The intestinal mucosa is highly adapted to be able to tolerate a large population of microorganisms and dietary antigens whilst preserving nutrient uptake and raising an effective immune response to pathogenic infection or commensal intrusion into the underlying host tissue [90]. For the most part, the microbiota maintains symbiosis with the gut environment forming a mutually beneficial relationship with the host. The gut provides a nutrient-rich habitat for the microbiota whilst the microbiota stimulates the host's immune system, aids digestion, and provides otherwise unobtainable metabolites. In a normal healthy gut, the microbiota is diverse with an abundance of beneficial bacteria that help to maintain gut homeostasis, promoting protective intestinal immune responses at the mucosal surface, and limiting excessive mucosal inflammation [91].

The microbiota can communicate directly with the host through host recognition of highly conserved structural components, termed microbe-associated molecular patterns (MAMPs) [92], such as lipopolysaccharides (LPSs), peptidoglycan (PGN), and flagellin. Recognition of MAMPs are achieved primarily through binding to




pattern-recognition receptors (PRRs) expressed by intestinal epithelial cells (IECs) and immune cells. PRRs are a diverse family of transmembrane and cytoplasmic innate immune receptors, that include Toll-like receptors (TLRs) and nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) [93]. PRR stimulation triggers intracellular signalling cascades leading to the expression of a range of immunomodulatory molecules that orchestrate early immune responses resulting in mucosal inflammation and further activation of innate and adaptive immune processes [94]. Whereas activation of PRR by pathogens and pathobionts is known to initiate pro-inflammatory signalling cascades that lead to mucosal inflammation, the commensal microbiota can use similar mechanisms to dampen inflammation and promote intestinal homeostasis [95]. For example, polysaccharide A (PSA) from the ubiquitous gut commensal *Bacteroides fragilis* (*B. fragilis*) is recognised by the TLR1/TLR2 heterodimer, in co-operation with the C-type lectin PRR Dectin-1, triggering a signalling cascade through the phosphoinositide 3-kinase (PI3K) pathway to promote 3',5'-cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)-dependent transcription of anti-inflammatory genes [96]. NOD2 stimulation by muramyl-dipeptide (MDP), a PGN motif, triggers intestinal leucine-rich repeat-containing G-protein coupled receptor 5 (*Lgr5*)<sup>+</sup> stem cell survival and epithelial regeneration [97]. In addition to microbe specific constituents, there are also numerous microbiota-derived metabolites, such as SCFA, that stimulate a range of signalling pathways to further regulate mucosal immune responses and aid microbial symbiosis/tolerance [98].

## Direct microbial maintenance of intestinal barrier integrity

The intestinal mucosa forms physical, biochemical, and immunological barriers which allow for the symbiotic microbiota–host relationship to be maintained, controlling the microbial population, and reducing direct contact with the host [99]. Maintenance of these barriers are essential for preventing microbial invasion, excessive immune responses, and mucosal inflammation. As well as defending against pathogens through competition for nutrients and production of antimicrobial molecules [100,101], the gut microbiota also plays an active role in the maintenance of host mucosal barriers, which further prevents colonisation by opportunistic pathogens, limiting excessive mucosal inflammation, and preserving gut homeostasis [99,100].

The physical barrier consists of a wall of IECs that are held together by cell junctions, particularly tight junctions (TJs), allowing only selective paracellular transport of water, ions, solutes, and some nutrients, preventing passage of microorganisms [102]. A mucus layer, predominantly formed of highly glycosylated mucins secreted by goblet cells, covers IECs and further contributes to the physical barrier preventing bacteria from interacting directly with host tissue [103]. The mucus layer also provides moisture and lubrication to protect IECs from dehydration and mechanical stress caused by the passage of food and peristaltic forces [104]. The small intestine contains one layer of mucus whereas the colon contains two: a loose outer layer that is permeable to bacteria and a dense inner layer that is impermeable and devoid of bacteria [105]. In the small intestine particularly, secretory molecules such as antimicrobial peptides (AMPs) and immunoglobulin (Ig)A are released and concentrated in the mucus layer, which further aid separation of the microbiota from the host mucosa [101,106]. In addition to targeting microbes directly and sequestering key nutrients to control microbiota biodiversity, these barriers can also modulate the host's innate and adaptive immune responses [107,108] and drive up-regulation of mucin and TJ protein expression in IECs to maintain intestinal barrier integrity [109,110].

Normal maturation and function of the mucus layer is strongly influenced by the gut microbiota, either through bacterial degradation and turn-over of mucin glycans or by bacteria-mediated processes to regulate host glycosylation of mucins [111]. Additionally, microbe-derived signals and metabolites have been shown to protect the intestinal epithelial barrier, up-regulating and strengthening cell junctions as well as promoting maintenance of the mucus layer and release of antimicrobial molecules (Figure 2). For example, indoles, which are microbiota-derived metabolites produced from the amino acid tryptophan have been shown to increase gene expression linked to TJ formation and mucus production [112,113]. Indoles further protect IECs through attenuation of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ )-mediated activation of nuclear factor  $\kappa$ -light-chain-enhancer of activated B cells (NF- $\kappa$ B), decreased expression of pro-inflammatory cytokine interleukin (IL)-8, reduced attachment of pathogenic *E. coli*, and increased expression of anti-inflammatory IL-10 [112]. Studies using mice have shown that indole 3-propionic acid (IPA) stimulates the pregnane X receptor (PXR) resulting in up-regulation of TJ proteins in enterocytes and down-regulation of TNF- $\alpha$  [114]. Urolithin A (UroA), a sole microbiota-derived metabolite produced from polyphenolic compounds also enhances intestinal barrier integrity by increasing TJ proteins in IECs through activation of aryl hydrocarbon receptor (AhR)-nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent pathways [115]. SCFAs, in particular butyrate, are the main energy source for colonocytes and are known to promote epithelial barrier integrity [116–119]. SCFAs are taken up by cells either by passive diffusion or facilitated by solute transporters such as



**Figure 2. The direct effect of microbiota-derived metabolites on intestinal barrier integrity**


Microbiota-derived metabolites play an important role in maintaining intestinal barrier integrity to prevent epithelial damage and limit mucosal inflammation. Metabolites of polyunsaturated fatty acids (PUFAs) via a GPR40-MEK-ERK pathway have been shown to prevent loss of TJ proteins. Indoles, SCFAs, UroA, and secondary bile acids have also been shown to increase expression of TJ proteins via pathways involving PXR, adenosine monophosphate-activated protein kinase (AMPK), AhR-Nrf2, and VDR, respectively. Indoles and SCFAs promote the production and secretion of mucin, reinforcing the mucus layer. SCFAs activate a mechanistic target of rapamycin (mTOR)-signal transducer and activator of transcription (STAT) 3 pathway in a GPR43-dependent manner to induce production of AMPs.

monocarboxylate-transporter 1 (MCT-1) and sodium-coupled MCT-1 (SMCT1) where they can then be detected by intracellular receptors such as peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) [120–122]. Alternatively, SCFAs may signal through G-protein coupled receptors (GPRs), such as GPR41, GPR43, and GPR109A, to activate signalling cascades that regulate immune responses [123–125]. SCFAs directly promote mucosal barrier integrity through induction of genes encoding TJ proteins [126], mucins [127], and AMPs [128]. The gut microbial-derived metabolite of polyunsaturated omega-6 fatty acid linoleic acid, 10-hydroxy-*cis*-12-octadecenoic acid (HYA), is able to ameliorate intestinal barrier damage and changes to cell junction proteins partially via a GPR40-mitogen activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway [129]. Secondary bile acids, such as lithocholic acid [48], produced by gut microbial conversion of primary bile acids, have also been shown to protect IECs from a TNF- $\alpha$ -induced decrease in TJ proteins through activation of the vitamin D receptor (VDR) [130].

## Mucosal immune regulation by the microbiota

The mucosal immune system is fundamental to intestinal barrier integrity and inflammation. The microbiota plays a vital role, especially in early life, in the maturation and regulation of host immunity to ensure mucosal inflammation is controlled and that the host can differentiate between commensal and pathogenic bacteria [131].

Commensal bacteria have long been associated with the correct development of mucosa-associated lymphoid tissues (MALT), in particular the gut-associated lymphoid tissue (GALT) which includes Peyer's patches. Early studies using germ-free (GF) mice have shown that the absence of a commensal microbiota correlates with extensive defects in lymphoid tissue architecture and immune responses [132]. A significant reduction in intra-epithelial lymphocytes (IELs), such as  $\alpha\beta$  and  $\gamma\delta$  IELs, as well as secretory IgA, is seen in GF mice (compared with their colonised counterparts), which can be reversed following microbial colonisation [133,134]. Gestational maternal colonisation in mice has been shown to increase immune cell subtypes including intestinal group 3 innate lymphoid cells (ILC3s) and F4/80<sup>+</sup> CD11c<sup>+</sup> mononuclear cells [135]. Pro-inflammatory IL-17<sup>+</sup> CD4<sup>+</sup> T helper (Th17) cells, which normally exist in large numbers in the lamina propria of the small intestine are absent from GF mice, however, they can be induced upon commensal colonisation [136–138]. This is most notable with segmented filamentous bacteria (SFB),



**Figure 3. Regulation of mucosal immunity by the intestinal microbiota**

The mucosal immune system is complex with cross-talk between both innate and adaptive components that are primed to counter pathogens and preserve mucosal barrier integrity. MAMPs and microbial-derived metabolites (MDMs) can directly influence this network, aiding the development of host immune responses against pathogens whilst also limiting excessive mucosal inflammation to ensure microbiota tolerance.

which upon adhesion to IECs, are known to stimulate T-cell responses as well as enhance IgA production [126,139]. PSA from *B. fragilis* aids cellular and physical maturation of the developing immune system in mice, correcting T-cell deficiencies and imbalances in CD4<sup>+</sup> T helper 1 (Th1) and Th2 cell subtypes, directing lymphoid organogenesis [140]. In neonatal mice, *B. fragilis* is also known to supplement the endogenous lipid antigen milieu with inhibitory sphingolipids, impeding invariant natural killer T (iNKT) cell proliferation in the colonic lamina propria, providing protection against iNKT cell-mediated mucosal inflammation and injury [141]. Microbial colonisation also influences the development of early B-cell lineages in the intestinal mucosa, modulating gut immunoglobulin repertoires [142]. Sufficient intestinal microbiota diversity during early life colonisation has been shown to be essential for the establishment of an immunoregulatory network that protects against elevated induction of IgE at mucosal sites, which is linked to immune hypersensitivity, mucosal inflammation, and allergies [72].

Beyond infancy, the gut microbiota continues to influence the host immune system to maintain host–microbiota symbiosis and intestinal homeostasis (Figure 3). For example, MAMPs and microbiota-derived metabolites can signal through activation of NLR complexes, called inflammasomes, to shape host immune responses and regulate mucosal barrier function. The microbiota induces NOD-, leucine-rich repeat (LRR)-, and pyrin domain containing 6 (NLRP6) inflammasome signalling to promote steady-state pro-inflammatory IL-18 mucosal secretion, which in turn activates AMP and mucin production in the intestinal mucosa, refining microbiota composition [143]. SCFAs signal through GPR43 and GPR109A to activate NLRP3 leading to IL-18 mucosal secretion [124]. Members of the microbiota, specifically *Proteus mirabilis*, can induce robust IL-1β production via the NLRP3 inflammasome to promote intestinal mucosal inflammation, mediated by monocytes that are recruited to the intestine in response to epithelial injury [144]. The sensing of PGN fragments and PGN from intact commensal bacteria through multiple PPRs is necessary for the proper development and activation of immune cells. Phagocytes sense internalised PGNs through NLRs and inflammasome complexes (e.g. NLRP3) which induce secretion of pro-inflammatory cytokines



(e.g. TNF- $\alpha$ , IL-6, IL-1 $\beta$ , and IL-18) as well as increase antimicrobial responses, such as reactive oxygen species (ROS) and AMP production [145]. Macrophages play a vital role as innate immune effector cells to maintain intestinal homeostasis, being able to initiate both pro-inflammatory and anti-inflammatory signalling pathways. In mice, intestinal microbial colonisation has been shown to drive continuous replenishment of macrophages in the intestinal mucosa by monocytes that express C-C chemokine receptor type 2 (CCR2) [146]. *Helicobacter hepaticus* induce an early IL-10 response in intestinal lamina propria-resident macrophages and produce a large soluble polysaccharide (LSP) that activates a specific mitogen and stress-activated protein kinase (MSK)/CREB-dependent anti-inflammatory signalling cascade via TLR2, aiding tolerance and mutualism [147]. Butyrate drives monocyte to macrophage differentiation through histone deacetylase (HDAC) 3 (HDAC3) inhibition to promote an antimicrobial state without inducing pro-inflammatory cytokine production [148]. Trimethylamine N-oxide (TMAO), the oxidated product of gut microbiota-derived trimethylamine, triggers M1 macrophage polarisation via NLRP3 inflammasome activation in mice resulting in Th1 and Th17 differentiation [149]. Furthermore, TMAO has been shown to prime the NLRP3 inflammasome and increase generation of ROS via inhibition of autophagy in colonic epithelial cells contributing to mucosal inflammation [150].

ILCs are a heterogeneous innate cell population that specialise in rapid secretion of polarising cytokines and are involved in the initiation of mucosal inflammation to fight infection and inflammatory resolution for mucosal tissue repair [151,152]. Many of the functions of ILCs are mediated by the microbiota [152,153]. For example, proliferation and function of colonic ILC3s is regulated by SCFA activation of GPR43. GPR43 agonism differentially activates protein kinase B (AKT) and ERK signalling, leading to increased colonic ILC3-derived IL-22, ensuring correct mucosal mucin and AMP production from IECs [154,155]. Dichotomous regulation of ILCs has been observed by a pair of *Helicobacter* species, activating ILCs but negatively regulating proliferation of ILC3s [156].


PSA mediates the conversion of CD4<sup>+</sup> cells into anti-inflammatory forkhead box P3 (Foxp3)<sup>+</sup> regulatory T (Treg) cells and subsequent production of IL-10, both via TLR2, to suppress mucosal inflammation [157]. SCFAs, such as butyrate and propionate, also induce Treg generation via HDAC inhibition [158]. Microbiota-derived secondary bile acids have recently been shown to regulate colonic retinoic acid receptor-related orphan receptor  $\gamma$  (ROR $\gamma$ )<sup>+</sup> Treg induction and homeostasis [159]. Indoles, such as indole-3-aldehyde, signal through AhR in immune cells to regulate IL-22 production and promote mucosal immune homeostasis [160]. Bacteria-derived B vitamins have an impact on many aspects of immunological maintenance [161]. Vitamins B1 and B2 act as cofactors for enzymes involved in the TCA cycle and are important for immunometabolism and immune cell differentiation [161,162]. Vitamin B2 is also associated with ROS generation in phagocytic immune cells through priming nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (NOX2) [163]. The vitamin B2 metabolite, 6-hydroxymethyl-8-D-ribityllumazine, bound to major histocompatibility complex (MHC) class I-related protein (MR1) on antigen-presenting cells (APCs), activates mucosal-associated invariant T (MAIT) cells to promote production of pro-inflammatory interferon- $\gamma$  (IFN- $\gamma$ ) and IL-17 [164]. In contrast, the vitamin B9 metabolite, acetyl-6-formylpterin, inhibits activation of MAIT cells [165]. Vitamin B3 binds to GPR109A on macrophages and dendritic cells leading to an increase in anti-inflammatory cytokines and Treg differentiation [166]. Vitamin B7 (biotin) suppresses the production of pro-inflammatory cytokines [167,168]. Vitamin B9 (folate) binds to the folate receptor 4 (FR4) on differentiated Tregs, promoting cell survival [161]. Vitamin B12 is required for CD8<sup>+</sup> T cell differentiation and NK cell activation [169].

As detailed, the intestinal microbiota is not functionally independent from the host mucosa, playing an important role in gut homeostasis. When there is a perturbation in this finely balanced relationship, loss of mucosal barrier integrity and a rise in abnormal immune responses can occur leading to a risk of sustained pathogenic inflammation and development of disease.

## Dysbiosis and disease

Environmental changes as well as host genetic susceptibility can contribute to dysbiosis [170,171]. In a dysbiotic state, altered relative abundances of certain microbial species and/or microbiota-derived metabolites can lead to the disruption of intestinal barrier integrity and host immune responses. Dysregulated mucosal immune responses are often characterised by an up-regulation of Th1, Th2, and Th17 cells and a down-regulation of Tregs and IgA [172,173]. Dysbiosis is linked to the development of numerous disease states including IBD, rheumatoid arthritis (RA), multiple sclerosis (MS), and metabolic syndrome [172,174] (Figure 4). However, it is worth noting that many of the studies to date, particularly those highlighting immunological pathways, have been solely based on findings from rodent models, which have inherent limitations [175].





**Figure 4. Linking dysbiosis and disease**

Several diseases have been linked to dysbiosis. A dysbiotic state is often characterised by a loss of beneficial microbes, increased levels of pathobionts, and a decrease in microbial diversity. Changes in relative bacterial abundance, as well as microbe-derived metabolites, are thought to cause dysregulation in host gut permeability, leading to a compromised immune response and in turn the development of disease.

## IBD

IBD is an umbrella term encompassing a group of complex chronic inflammatory disorders of the gastrointestinal tract [176]. Most commonly in the form of Crohn's disease (CD) and ulcerative colitis (UC), IBD has been associated with changes in gut microbiota. However, it is not clear whether these changes contribute to disease pathogenesis or develop because of disease-related inflammation. IBD patients exhibit a reduction in microbiota size, functional diversity, and stability compared with healthy controls. In general, the microbiome of IBD patients show a decrease in Firmicutes of the *Clostridium leptum* group, particularly *Faecalibacterium prausnitzii* (*F. prausnitzii*), and an increase in Bacteroidetes and Proteobacteria such as *Desulfovibrio desulfuricans* (*D. desulfuricans*) and *E. coli* [177–179]. On average, IBD patients harbour 25% less microbial genes than a healthy person [180].

The changes observed in the gut microbiome of IBD patients have been linked to bacteria known to have a role in either suppressing or promoting inflammation. Individuals with CD have a lower abundance of *F. prausnitzii*, an SCFA-producing bacterium, that promotes good gut health through up-regulation of Tregs and anti-inflammatory cytokines [181,182]. In humans, a reduction in *F. prausnitzii* is associated with an increased risk of postoperative recurrence of CD [182]. Furthermore, in IBD patients, an increase in the abundance of sulphate-reducing bacteria, such as *D. desulfuricans*, is attributed to increased production of hydrogen sulphate, which can damage IECs and in turn induce mucosal inflammation [183,184]. Several human studies have also reported a mucosa-associated *E. coli* richness in CD patients [179,185], leading to increased gut permeability and inflammation [186]. Both human and murine models have found that a reduction in tryptophan levels are also associated with IBD [187,188]. In IBD patients, tryptophan serum levels were found to inversely correlate with IL-22 levels and disease activity [187].

## Coeliac disease

Coeliac disease, prevalent in 1–2% of the global population, is an immune-mediated inflammatory disorder that primarily affects the small intestine and is initiated following ingestion of gluten in genetically predisposed individuals [189,190]. Research has suggested that dysbiosis plays a role in triggering coeliac disease with a dysregulated immune response and failure to maintain intestinal barrier integrity, leading to mucosal inflammation [191]. However, like IBD, it remains unclear as to whether the dysbiotic state characteristic of coeliac disease is a cause or consequence of a dysregulated immune response.

As coeliac disease generally presents in childhood and young adulthood, most studies looking at a link between coeliac disease and the microbiome have focused on children [191]. Rod-shaped bacteria, including Clostridia, *Prevotella*, and *Actinomyces*, are more frequently found in the small bowel of children with active coeliac compared with healthy controls [192]. Whilst no consistent microbial signature has been determined for patients with coeliac disease, most studies report an imbalance between Gram-negative and Gram-positive bacteria, characterised by both an increase in Gram-negative *Bacteroides* and *Proteobacteria*, and a decrease in Gram-positive *Lactobacilli* and *Bifidobacteria*, which have a protective anti-inflammatory effect [193,194]. Experimental murine models have reported that some *Bacteroidetes* species are involved in the disruption of intestinal barrier integrity, exhibiting pro-inflammatory effects [46,195,196]. Both mice and human studies have shown that *Lactobacilli* and *Bifidobacteria* may play a role in modifying the immunogenic potential of gluten, through breakdown of both gluten and its peptide derivatives [197,198]. For example, *Lactobacilli* can detoxify gliadin peptides after their partial digestion by human proteases. Both mice and human studies report that *Bifidobacterium* strains also play a role in reducing the epithelial permeability triggered by gluten, diminishing pro-inflammatory cytokine synthesis and decreasing jejunal barrier damage [199–201].

Whilst the exact mechanisms involved in coeliac disease remain unclear, studies in mice have shown that a dysbiotic microbiota can result in increased levels of LPS in the intestine, which result in a dysregulation of the immune response through the activation of both IELs and IECs, triggering the production of AMPs and mucin [202,203]. Additionally, mouse studies have linked alterations in microbial metabolites to the induction of Treg cells and dendritic cells, which produce IL-10 and retinoic acid and thereby contribute to the activation of various cellular inflammatory processes within the lamina propria [158,204].

## Other autoimmune diseases

RA is a systemic autoimmune disorder that results in joint destruction, affecting approximately 0.5–1% of the global population [205]. Patients with RA exhibit decreased gut microbial diversity and microbial gut dysbiosis characterised by an abundance of *Prevotella*, *Lactobacilli*, and *Collinsella* [206–208]. Mouse models show that *Prevotella* and *Collinsella* can induce a pro-inflammatory Th17 response and increase gut permeability [206]. Colonisation of K/BxN mice, an established RA model, with SFB was shown to induce Th17 cell proliferation, ultimately leading to the differentiation of B cells and the production of autoantibodies [209]. It is thought that these autoantibodies target joints, leading to the inflammation seen in RA.

MS is a neurodegenerative autoimmune disease that affects the central nervous system (CNS) [210]. Whilst a typical microbiota phenotype for MS has not yet been described, patients with active disease generally exhibit decreased species richness, an abundance of *Anaerostipes*, *Faecalibacteria*, and *Psuedomonas*, and decreased levels of *Bacteroides*, *Prevotella*, *Parabacteroides* and *Adlercreutzia* [211,212]. An autoimmune encephalomyelitis (EAE) GF mouse model, which is also a model for MS, showed lower levels of IL-17 in both the gut and CNS, and an increase in peripheral Tregs [213]. Furthermore, disease severity in EAE models is also closely related to altered intestinal permeability, reduced submucosa thickness, and altered TJ expression in IECs [214,215].

## Metabolic syndrome

Metabolic syndrome describes a group of risk factors, including obesity, hyperglycaemia, hypertension, and dyslipidaemia, which can lead to the development of various conditions including cardiovascular disease. The pathogenesis of metabolic syndrome is linked to a variety of factors such as insulin resistance, chronic low-grade inflammation in metabolic tissue, and oxidative stress [216]. In recent years, gut dysbiosis has been identified as a risk factor for metabolic syndrome [217]. It is believed that environmental factors, such as a high-fat diet, linked to decreased microbial diversity, promotes both general and metabolic tissue inflammation that may lead to the development of metabolic syndrome.

The links between the gut microbiota and both obesity and type 2 diabetes (T2D) have been most extensively studied. Studies in mice have shown that transplantation of gut microbiota from obese to lean GF mice resulted in an obesogenic phenotype [218]. Furthermore, GF mice fed a high-fat, high-sugar diet were found to be resistant to weight gain [219]. Studies in humans suggest that compared with lean individuals, obese individuals have increased levels of Firmicutes and decreased levels of *Bacteroidetes* [220,221]. In both humans and murine models, Roux-en-Y gastric bypass surgery has been found to rapidly change the gut microbiota, with gut microbiota normalising close to non-obese controls [222,223]. Patients with T2D typically exhibit reduced microbiome diversity, reduced SCFA-producing bacteria, and an increased number of opportunistic pathogens [224]. Rodent studies have found that SCFA play a key role in metabolic disorders, particularly in obesity and T2D. The SCFAs, propionate and acetate,

were found to influence gut motility, intestinal transit rate, and caloric energy extraction from the diet through GPR41 activation [225]. Increased insulin sensitivity and increased satiety was also observed in mouse models, thought to be linked to the induction of glucagon-like peptide (GLP)-1 secretion through the activation of GPR43 and GPR41 [226]. Butyrate provides energy to enterocytes by exerting a trophic effect and inducing GLP-2 synthesis that in turn strengthens the gut barrier function [227].

It has been suggested that the gut microbial dysbiosis experienced in metabolic disorders leads to impaired intestinal cell function and increased gut permeability, partly induced by a high-fat diet [228]. Rodent studies have reported an increase in Gram-negative bacteria, including Proteobacteria, leading to a local increase in LPS in the mucosal layer [229,230]. MAMPs and microbiota-derived metabolites, including LPS, can translocate through the epithelial layer and reach the lamina propria where they are internalised by phagocytes. Furthermore, it has been hypothesised that microbial gut dysbiosis impairs communication between phagocytes and other immune cells in animal models, allowing the translocation of bacterial components to metabolic tissue [231,232]. In the metabolic tissue of mice, bacterial components trigger inflammation by promoting the proliferation of preadipocytes and macrophages, increasing ILC3 frequency and increasing the infiltration of B and T lymphocytes. Associated pro-inflammatory cytokines can also contribute to reduced insulin signalling, exacerbating the effects of diabetes.

## Microbiota-targeted therapies

As detailed previously, dysbiosis in the gut is implicated in multiple gastrointestinal and non-gastrointestinal diseases. Intervention aiming to ameliorate this pathological environment with the delivery of targeted beneficial or wholesale bacterial populations in the form of probiotics and faecal microbiota transplantation (FMT), respectively, has been in clinical practice for many years [233,234]. The various mechanisms by which probiotics and FMT exert their therapeutic effect has been reviewed in detail elsewhere [235–237], but centre their interaction with the host mucosal immune system via MAMPs [238,239] or extracellular vesicles [240–242], the surrounding microbiota via AMPs [243], microbial cross-feeding [244] or nutrient competition, and their contribution to the broader mucosal metabolic environment [118,148]. Here we review the latest developments and innovations in probiotics and FMT.

## Probiotics

The main probiotic genera, including Lactobacilli, Bifidobacteria, Saccharomyces, and Streptococci, as well as combination commercial probiotics, have been researched extensively and touted as potential therapies for many diseases or symptoms [245]. Certain probiotic strains have discrete effects on mucosal immune function, such as that seen with *Lactobacillus plantarum* TIFN1010 which modulates gene transcription pathways related to cell-cell adhesion and mucosal healing processes [238]. However, robust clinical data to support their use remain limited, with systematic reviews in IBD [246–248], Irritable bowel syndrome (IBS) [249] and *C. difficile*-associated diarrhoea (CDAD) [250] showing neutral or only qualified evidence for use. Similarly, practice guidelines do not recommend the routine use of probiotics [233], partly due to uncertainty regarding species or strain-dependent effects [251,252].

Recent advances in genomic sequencing and metabolic modelling have offered a way to reduce microbial uncertainty and the chance to optimise probiotic use through genetic engineering tools such as CRISPR-Cas [253–256]. For example, genetic modification of *Lactobacillus casei* (*L. casei*) to overexpress the *mcra* gene, and so enhance bioactive compound production, such as conjugate linoleic acid, can result in elimination of *Campylobacter jejuni*, an important diarrhoea-associated pathogen [257]. As well as optimising established probiotic species such as *L. casei*, confirmation of species such as *Akkermansia muciniphilia* (*A. muciniphilia*) as probiotic therapeutic candidates has become possible through the use of genome-scale modelling. Using this method, the complete microbial genome sequence can be screened to predict genes that influence particular metabolic pathways [258]. For *A. muciniphilia*, genes linked to sugar degradation and vitamin biosynthesis, as well as SCFA production, were predicted using this approach and validated by transcriptomic and proteomic analysis *in vitro* [259]. Antibiotic resistance and metabolic variation can also be assessed by whole-genome assembly undertaken on patient-derived stool samples [260]. Genomic sequencing technology has also been used to identify individuals resistant to probiotic colonisation at the mucosal level [261], allowing therapy to then be tailored, reducing treatment variability currently seen with probiotics [262].

Overall, whilst significant advances in probiotic therapy have been made, there is a need for a greater understanding of probiotic formulation, in addition to a requirement for more robust human clinical trial data to justify its routine use.

## Postbiotics

An important additional consideration regarding probiotic preparations is the intrinsic effect of microbial cell surface components and metabolites. Whereas, by definition, probiotics are live microorganisms [263], there is also a role for postbiotics, as inanimate microorganisms and/or their components [264], prepared specifically for their health benefits on the host. These narrow criteria exclude purified microbial metabolites applied in isolation and instead focus on thermal inactivation and quantification of products that possess microbial effector molecules such as bile salt hydrolase [265] and exopolysaccharides [239].

Murine studies have shown the effect of postbiotics on gastrointestinal mucosa in a *Citrobacter*-induced colitis model [266], whereas the mechanistic impact on mucosal inflammation in humans is more limited to specific metabolites such as butyrate as in the case of diversion colitis [267]. However, clinical studies focussing on subjective outcomes such as symptom scores have shown benefit of postbiotics in IBS [268].

To date, the application of postbiotics in gastrointestinal disease remains limited with the mainstay of evidence [269,270] and regulation [271], centred on secondary prevention of respiratory infections. Further mechanistic and clinical trial data are required to characterise the effect of specific postbiotics on gastrointestinal inflammation.

## FMT

FMT, the delivery of donor stool into the gastrointestinal tract of a patient, is an established and guideline-supported intervention for rCDI [234,272,273], independent of route of delivery [274], and a potential option in severe primary CDI [275]. Meta-analysis has indicated a positive association between FMT and the treatment of IBD, particularly with active UC [276,277]. Further trials are currently underway [278] to confirm FMT efficacy before being adopted into routine clinical practice [279]. Similarly, with CD, there is evidence supporting the benefits of FMT [280], however, it has not yet been recommended for clinical use [281]. Evidence remains lacking for routine use of FMT in IBS [282] with evidence for only conditional use in metabolic syndrome [283,284] and hepatic encephalopathy [285]. The use of FMT in non-gastrointestinal diseases is an area of ongoing study with randomised clinical trials in type 1 diabetes showing promise [286]. FMT clinical trials are also underway to assess effectivity in treating Coeliac disease (NCT04014413), RA (NCT03944096), Sjogren's syndrome (NCT03926286) and MS (NCT03183869; NCT03975413; NCT04150549), building upon prior animal and uncontrolled human studies [287]. It is in malignancy, and specifically anticancer immunotherapies, where microbiota and their manipulation have shown great promise, building on evidence that certain genera, for example, *Bifidobacteria* [288] or *Bacteroides* [289], can affect the efficacy of malignant melanoma treatments. A recent clinical trial revealed that some patients refractory to anti-programmed cell death protein 1 (PD-1) immunotherapy could overcome this resistance to therapy by undergoing FMT from donors who were responders to the same anti-PD-1 immunotherapy [290]. PD-1 is an immune checkpoint receptor on T cells that prevents overstimulation of immune responses and contributes to the maintenance of immune tolerance to self-antigens. The fact that FMT impacts on anti-PD-1 melanoma therapy demonstrates that the composition of the microbiota influences host systemic immune responses. FMT is now being applied to metastatic hormone-resistant prostate cancer (NCT04116775) and to ameliorate chemotherapy-induced toxicity (NCT04040712).

An important factor in FMT is the role of viruses and mycobiota given that whole stool transplantation involves a transfer of these microorganisms to the new host along with bacteria. Bacteriophages contribute to host immunity by adhering to mucosal mucus creating an additional antimicrobial layer that reduces bacterial attachment and colonisation of the mucosa [291]. Both *Caudovirales* [292] and *Saccharomyces* [293] have been shown as important drivers for successful treatment of rCDI by FMT. Faecal filtrate transfer (FFT), a supernatant composed of bacterial debris, AMPs, metabolic products and oligonucleotides, but not live bacteria, was also seen to improve outcomes in rCDI [294].

A limitation of widespread FMT use outside of the trial setting is the conceptual acceptability of single or pooled donor stool being transferred to a patient. Synthetic microbiomes can be cultured from donors and purified, or compiled from metagenomic studies [295]. Purified intestinal bacterial culture have been shown to be as effective in treating rCDI in a proof-of-principle study [296]. A recent randomised-controlled trial reported that a 12-strain bacterial mixture cultured from donor stool was inferior to conventional FMT but equivalent to using vancomycin for the treatment of rCDI [297]. FMT using freeze-dried or lyophilised matter has been shown in observational studies to also be effective in treating rCDI [298], with a propagated, lyophilised and encapsulated formulation currently under investigation in clinical trials for the treatment of rCDI (NCT02865616), UC (NCT03832400), and other diseases. These technologies, if efficacy is confirmed, herald the opportunity of a 'post-FMT' treatment model centred on highly selected donors yielding a purified, standardised, and cryopreserved microbiota preparation for systematic clinical use.



## Conclusion

The microbiome is a metabolically and immunologically active presence within the gastrointestinal tract that plays a vital role in the maintenance of human health. This population of highly diverse microorganisms is shaped by numerous factors, most notably, diet and the use of medications such as antibiotics. The intestinal mucosa provides an important interface between the microbiota and host, where the microbiota not only aids in development of effective host immune responses against pathogens and injury but also limits excessive mucosal inflammation to promote tolerance and stability of the gut environment. Microbial components and microbe-derived metabolites contribute to both mucosal barrier integrity and the regulation of underlying immune responses to preserve intestinal homeostasis. When there is a loss of this balanced relationship, as seen in dysbiosis, then there is a risk of sustained pathogenic inflammation and the development of numerous diseases. As our understanding of the microbiome and microbiota–host interactions has improved, so has our ability to harness members of the microbiota to reverse dysbiosis, reduce mucosal inflammation, and prevent disease progression. The outcome of ongoing clinical trials and mechanistic studies will hopefully extend our current knowledge of the microbiome and further our understanding of the role it plays in mucosal inflammation.

## Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

## Funding

This work was supported by the NIHR Biomedical Research Centre at University College London Hospital NHS Foundation and University College London [grant number BRC727/OHD/AS/110380 (to D.J.S. and A.M.S.)]; and the Crohn's & Colitis U.K. Fellowship [grant number 2019-4 Smith (Sebepos-Rogers); award number 179344 (to G.S.-R.)].

## Open Access

Open access for this article was enabled by the participation of University College London in an all-inclusive *Read & Publish* pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.

## Author Contribution

D.J.S., S.I., and G.S.-R. wrote the manuscript. D.J.S. produced the figures. A.M.S. and F.Z.R. revised the manuscript. All authors read and approved the final manuscript.

## Abbreviations

AhR, aryl hydrocarbon receptor; AMP, antimicrobial peptide; CD, Crohn's disease; CNS, central nervous system; CREB, cAMP response element-binding protein; C-section, caesarean section; EAE, autoimmune encephalomyelitis; ERK, extracellular signal-regulated kinase; FMT, faecal microbiota transplantation; GF, germ-free; GLP, glucagon-like peptide; GPR, G-protein coupled receptor; HDAC, histone deacetylase; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; IEC, intestinal epithelial cell; IEL, intra-epithelial lymphocyte; IL, interleukin; ILC, innate lymphoid cell; ILC3, intestinal group 3 innate lymphoid cell; LPS, lipopolysaccharide; MAIT, mucosal-associated invariant T; MAMP, microbe-associated molecular pattern; MS, multiple sclerosis; NLR, nucleotide-binding oligomerisation domain (NOD)-like receptor; NLRP, NOD-, leucine-rich repeat (LRR)-, and pyrin domain containing; NOD, nucleotide-binding oligomerisation domain; PD-1, programmed cell death protein 1; PGN, peptidoglycan; PPI, proton pump inhibitor; PRR, pattern-recognition receptor; PSA, polysaccharide A; RA, rheumatoid arthritis; rCDI, recurrent *Clostridium difficile* infection; ROS, reactive oxygen species; SCFA, short-chain fatty acid; Th, T helper; TJ, tight junction; TLR, Toll-like receptor; TMAO, trimethylamine N-oxide; TNF- $\alpha$ , tumour necrosis factor- $\alpha$ ; Treg, regulatory T; T2D, type 2 diabetes; UC, ulcerative colitis.

## References

- 1 Dethlefsen, L., McFall-Ngai, M. and Relman, D.A. (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. *Nature* **449**, 811–818, <https://doi.org/10.1038/nature06245>
- 2 Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C.M., Knight, R. and Gordon, J.I. (2007) The human microbiome project. *Nature* **449**, 804–810, <https://doi.org/10.1038/nature06244>
- 3 Sender, R., Fuchs, S. and Milo, R. (2016) Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol.* **14**, e1002533, <https://doi.org/10.1371/journal.pbio.1002533>
- 4 Koskinen, K., Pausan, M.R., Perras, A.K., Beck, M., Bang, C., Mora, M. et al. (2017) First insights into the diverse human archaeome: specific detection of archaea in the gastrointestinal tract, lung, and nose and on skin. *mBio* **8**, e00824–17, <https://doi.org/10.1128/mBio.00824-17>

- 5 Kumata, R., Ito, J., Takahashi, K., Suzuki, T. and Sato, K. (2020) A tissue level atlas of the healthy human virome. *BMC Biol.* **18**, 55, <https://doi.org/10.1186/s12915-020-00785-5>
- 6 Ghannoum, M.A., Jurevic, R.J., Mukherjee, P.K., Cui, F., Sikaroodi, M., Naqvi, A. et al. (2010) Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog.* **6**, e1000713, <https://doi.org/10.1371/journal.ppat.1000713>
- 7 Nieves-Ramirez, M.E., Partida-Rodriguez, O., Laforest-Lapointe, I., Reynolds, L.A., Brown, E.M., Valdez-Salazar, A. et al. (2018) Asymptomatic intestinal colonization with protist blastocystis is strongly associated with distinct microbiome ecological patterns. *mSystems* **3**, e00007–18, <https://doi.org/10.1128/mSystems.00007-18>
- 8 Sender, R., Fuchs, S. and Milo, R. (2016) Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. *Cell* **164**, 337–340, <https://doi.org/10.1016/j.cell.2016.01.013>
- 9 Tierney, B.T., Yang, Z., Lubber, J.M., Beaudin, M., Wibowo, M.C., Baek, C. et al. (2019) The landscape of genetic content in the gut and oral human microbiome. *Cell Host Microbe* **26**, 283.e8–295.e8, <https://doi.org/10.1016/j.chom.2019.07.008>
- 10 Bharti, R. and Grimm, D.G. (2019) Current challenges and best-practice protocols for microbiome analysis. *Brief. Bioinform.*, <https://doi.org/10.1093/bib/bbz155>
- 11 Integrative HMP RNC (2019) The Integrative Human Microbiome Project. *Nature* **569**, 641–648, <https://doi.org/10.1038/s41586-019-1238-8>
- 12 Zhao, L., Ni, Y., Su, M., Li, H., Dong, F., Chen, W. et al. (2017) High throughput and quantitative measurement of microbial metabolome by gas chromatography/mass spectrometry using automated alkyl chloroformate derivatization. *Anal. Chem.* **89**, 5565–5577, <https://doi.org/10.1021/acs.analchem.7b00660>
- 13 Mas-Lloret, J., Obon-Santacana, M., Ibanez-Sanz, G., Guino, E., Pato, M.L., Rodriguez-Moranta, F. et al. (2020) Gut microbiome diversity detected by high-coverage 16S and shotgun sequencing of paired stool and colon sample. *Sci. Data* **7**, 92, <https://doi.org/10.1038/s41597-020-0427-5>
- 14 Tauzin, A.S., Pereira, M.R., Van Vliet, L.D., Colin, P.Y., Laville, E., Esque, J. et al. (2020) Investigating host-microbiome interactions by droplet based microfluidics. *Microbiome* **8**, 141, <https://doi.org/10.1186/s40168-020-00911-z>
- 15 Wilkins, L.J., Monga, M. and Miller, A.W. (2019) Defining dysbiosis for a cluster of chronic diseases. *Sci. Rep.* **9**, 12918, <https://doi.org/10.1038/s41598-019-49452-y>
- 16 Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D. et al. (2018) Environment dominates over host genetics in shaping human gut microbiota. *Nature* **555**, 210–215, <https://doi.org/10.1038/nature25973>
- 17 Shaw, L., Ribeiro, A.L.R., Levine, A.P., Pontikos, N., Balloux, F., Segal, A.W. et al. (2017) The human salivary microbiome is shaped by shared environment rather than genetics: evidence from a large family of closely related individuals. *mBio* **8**, e01237–17, <https://doi.org/10.1128/mBio.01237-17>
- 18 Luissint, A.C., Parkos, C.A. and Nusrat, A. (2016) Inflammation and the intestinal barrier: leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair. *Gastroenterology* **151**, 616–632, <https://doi.org/10.1053/j.gastro.2016.07.008>
- 19 Jalanka-Tuovinen, J., Salonen, A., Nikkilä, J., Immonen, O., Kekkonen, R., Lahti, L. et al. (2011) Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. *PLoS ONE* **6**, e23035, <https://doi.org/10.1371/journal.pone.0023035>
- 20 Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M. et al. (2005) Diversity of the human intestinal microbial flora. *Science* **308**, 1635–1638, <https://doi.org/10.1126/science.1110591>
- 21 Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C. et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* **464**, 59–65, <https://doi.org/10.1038/nature08821>
- 22 Jung, Y., Kerfahi, D., Quang Pham, H., Hyunwoo, S., Ibal, J., Park, M. et al. (2020) Although host-related factors are important for the formation of gut microbiota, environmental factors cannot be ignored. *bioRxiv*, <https://doi.org/10.1101/2020.02.03.93331>
- 23 Kim, M. and Benayoun, B.A. (2020) The microbiome: an emerging key player in aging and longevity. *Transl. Med. Aging* **4**, 103–116
- 24 Nagpal, R., Mainali, R., Ahmadi, S., Wang, S., Singh, R., Kavanagh, K. et al. (2018) Gut microbiome and aging: Physiological and mechanistic insights. *Nutr. Healthy Aging* **4**, 267–285
- 25 Gupta, V.K., Paul, S. and Dutta, C. (2017) Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. *Front. Microbiol.* **8**, 1162, <https://doi.org/10.3389/fmicb.2017.01162>
- 26 Reyman, M., van Houten, M.A., van Baarle, D., Bosch, A.A.T.M., Man, W.H., Chu, M.L.J.N. et al. (2019) Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life. *Nat. Commun.* **10**, 4997
- 27 Rutayisire, E., Huang, K., Liu, Y. and Tao, F. (2016) The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants' life: a systematic review. *BMC Gastroenterol.* **16**, 86
- 28 Rodríguez, J.M., Murphy, K., Stanton, C., Ross, R.P., Kober, O.I., Juge, N. et al. (2015) The composition of the gut microbiota throughout life, with an emphasis on early life. *Microb. Ecol. Health Dis.* **26**, 26050
- 29 Leeming, E.R., Johnson, A.J., Spector, T.D. and Le Roy, C.I. (2019) Effect of diet on the gut microbiota: rethinking intervention duration. *Nutrients* **11**, 2862
- 30 Zinöcker, M.K. and Lindseth, I.A. (2018) The Western diet-microbiome-host interaction and its role in metabolic disease. *Nutrients* **10**, 365
- 31 Hasegawa, Y., Chen, S.-Y., Sheng, L., Jena, P.K., Kalanetra, K.M., Mills, D.A. et al. (2020) Long-term effects of western diet consumption in male and female mice. *Sci. Rep.* **10**, 14686, <https://doi.org/10.1038/s41598-020-71592-9>
- 32 De Filippis, F., Pellegrini, N., Vannini, L., Jeffery, I.B., La Storia, A., Laghi, L. et al. (2016) High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. *Gut* **65**, 1812, <https://doi.org/10.1136/gutjnl-2015-309957>
- 33 Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H. and Kovatcheva-Datchary, P. (2015) Dynamics and stabilization of the human gut microbiome during the first year of life resource. *Cell Host Microbe* **17**, 690–703, <https://doi.org/10.1016/j.chom.2015.04.004>

- 34 Rautava, S. (2016) Early microbial contact, the breast milk microbiome and child health. *J. Dev. Origins Health Dis.* **7**, 5–14, <https://doi.org/10.1017/S2040174415001233>
- 35 Lawson, M.A.E., O'Neill, I.J., Kujawska, M., Gowrinadh Javvadi, S., Wijeyesekera, A., Flegg, Z. et al. (2020) Breast milk-derived human milk oligosaccharides promote Bifidobacterium interactions within a single ecosystem. *ISME J.* **14**, 635–648, <https://doi.org/10.1038/s41396-019-0553-2>
- 36 Marcobal, A., Barboza, M., Froehlich, J.W., Block, D.E., German, J.B., Lebrilla, C.B. et al. (2010) Consumption of human milk oligosaccharides by gut-related microbes. *J. Agric. Food Chem.* **58**, 5334–5340, <https://doi.org/10.1021/jf9044205>
- 37 Lyons, K.E., Ryan, C.A., Dempsey, E.M., Ross, R.P. and Stanton, C. (2020) Breast milk, a source of beneficial microbes and associated benefits for infant health. *Nutrients* **12**, 1039, <https://doi.org/10.3390/nu12041039>
- 38 Fallani, M., Amarri, S., Uusjarvi, A., Adam, R., Khanna, S., Aguilera, M. et al. (2011) Determinants of the human infant intestinal microbiota after the introduction of first complementary foods in infant samples from five European centres. *Microbiology* **157**, 1385–1392, <https://doi.org/10.1099/mic.0.042143-0>
- 39 Wu, G.D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.Y., Keilbaugh, S.A. et al. (2011) Linking long-term dietary patterns with gut microbial enterotypes. *Science* **334**, 105–108, <https://doi.org/10.1126/science.1208344>
- 40 Reddy, B.S., Weisburger, J.H. and Wynder, E.L. (1975) Effects of high risk and low risk diets for colon carcinogenesis on fecal microflora and steroids in man. *J. Nutr.* **105**, 878–884, <https://doi.org/10.1093/jn/105.7.878>
- 41 Drasar, B.S., Crowther, J.S., Goddard, P., Hawksworth, G., Hill, M.J., Peach, S. et al. (1973) The relation between diet and the gut microflora in man. *Proc. Nutr. Soc.* **32**, 49–52, <https://doi.org/10.1079/PNS19730014>
- 42 Bisanz, J.E., Upadhyay, V., Turnbaugh, J.A., Ly, K. and Turnbaugh, P.J. (2019) Meta-analysis reveals reproducible gut microbiome alterations in response to a high-fat diet. *Cell Host Microbe* **26**, 265.e4–272.e4, <https://doi.org/10.1016/j.chom.2019.06.013>
- 43 Moreira, A.P., Teixeira, T.F., Ferreira, A.B., Peluzio Mdo, C. and Alfenas Rde, C. (2012) Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. *Br. J. Nutr.* **108**, 801–809, <https://doi.org/10.1017/S0007114512001213>
- 44 Gerasimidis, K., Bryden, K., Chen, X., Papachristou, E., Verney, A., Roig, M. et al. (2020) The impact of food additives, artificial sweeteners and domestic hygiene products on the human gut microbiome and its fibre fermentation capacity. *Eur. J. Nutr.* **59**, 3213–3230, <https://doi.org/10.1007/s00394-019-02161-8>
- 45 Partridge, D., Lloyd, K.A., Rhodes, J.M., Walker, A.W., Johnstone, A.M. and Campbell, B.J. (2019) Food additives: Assessing the impact of exposure to permitted emulsifiers on bowel and metabolic health - introducing the FADiets study. *Nutr. Bull.* **44**, 329–349, <https://doi.org/10.1111/mbu.12408>
- 46 Sydora, B.C., MacFarlane, S.M., Walker, J.W., Dmytrash, A.L., Churchill, T.A., Doyle, J. et al. (2007) Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. *Inflamm. Bowel Dis.* **13**, 947–954, <https://doi.org/10.1002/ibd.20155>
- 47 Del Chierico, F., Vernocchi, P., Dallapiccola, B. and Putignani, L. (2014) Mediterranean diet and health: food effects on gut microbiota and disease control. *Int. J. Mol. Sci.* **15**, 11678–11699, <https://doi.org/10.3390/ijms150711678>
- 48 Garcia-Mantrana, I., Selma-Royo, M., Alcantara, C. and Collado, M.C. (2018) Shifts on gut microbiota associated to mediterranean diet adherence and specific dietary intakes on general adult population. *Front. Microbiol.* **9**, 890, <https://doi.org/10.3389/fmicb.2018.00890>
- 49 Heiman, M.L. and Greenway, F.L. (2016) A healthy gastrointestinal microbiome is dependent on dietary diversity. *Mol. Metab.* **5**, 317–320, <https://doi.org/10.1016/j.molmet.2016.02.005>
- 50 Zarrinpar, A., Chaix, A., Yooseph, S. and Panda, S. (2014) Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. *Cell Metab.* **20**, 1006–1017, <https://doi.org/10.1016/j.cmet.2014.11.008>
- 51 Kaczmarek, J.L., Musaad, S.M. and Holscher, H.D. (2017) Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota. *Am. J. Clin. Nutr.* **106**, 1220–1231, <https://doi.org/10.3945/ajcn.117.156380>
- 52 De Filippis, F., Vitaglione, P., Cuomo, R., Berni Canani, R. and Ercolini, D. (2018) Dietary interventions to modulate the gut microbiome—how far away are we from precision medicine. *Inflamm. Bowel Dis.* **24**, 2142–2154, <https://doi.org/10.1093/ibd/izy080>
- 53 Zhang, C., Li, S., Yang, L., Huang, P., Li, W., Wang, S. et al. (2013) Structural modulation of gut microbiota in life-long calorie-restricted mice. *Nat. Commun.* **4**, 2163, <https://doi.org/10.1038/ncomms3163>
- 54 Santacruz, A., Marcos, A., Wärnberg, J., Martí, A., Martín-Matillas, M., Campoy, C. et al. (2009) Interplay between weight loss and gut microbiota composition in overweight adolescents. *Obesity* **17**, 1906–1915, <https://doi.org/10.1038/oby.2009.112>
- 55 Kurup, K., Matyi, S., Giles, C.B., Wren, J.D., Jones, K., Ericsson, A. et al. (2021) Calorie restriction prevents age-related changes in the intestinal microbiota. *Aging (Albany N.Y.)* **13**, 6298–6329, <https://doi.org/10.18632/aging.202753>
- 56 Zheng, X., Wang, S. and Jia, W. (2018) Calorie restriction and its impact on gut microbial composition and global metabolism. *Front. Med.* **12**, 634–644, <https://doi.org/10.1007/s11684-018-0670-8>
- 57 Klingensmith, N.J. and Coopersmith, C.M. (2016) The gut as the motor of multiple organ dysfunction in critical illness. *Crit. Care Clin.* **32**, 203–212, <https://doi.org/10.1016/j.ccc.2015.11.004>
- 58 Nguyen, L.H., Örtqvist, A.K., Cao, Y., Simon, T.G., Roelstraete, B., Song, M. et al. (2020) Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. *Lancet Gastroenterol. Hepatol.* **5**, 986–995, [https://doi.org/10.1016/S2468-1253\(20\)30267-3](https://doi.org/10.1016/S2468-1253(20)30267-3)
- 59 Kim, D.H., Han, K. and Kim, S.W. (2018) Effects of antibiotics on the development of asthma and other allergic diseases in children and adolescents. *Allergy Asthma Immunol. Res.* **10**, 457–465, <https://doi.org/10.4168/aaair.2018.10.5.457>
- 60 Bhalodi, A.A., van Engelen, T.S.R., Virk, H.S. and Wiersinga, W.J. (2019) Impact of antimicrobial therapy on the gut microbiome. *J. Antimicrob. Chemother.* **74**, i6–i15, <https://doi.org/10.1093/jac/dky530>
- 61 Panda, S., El khader, I., Casellas, F., López Vivancos, J., García Cors, M., Santiago, A. et al. (2014) Short-term effect of antibiotics on human gut microbiota. *PLoS ONE* **9**, e95476, <https://doi.org/10.1371/journal.pone.0095476>

- 62 Scott, N.A., Andrusaitė, A., Andersen, P., Lawson, M., Alcon-Giner, C., Leclaire, C. et al. (2018) Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. *Sci. Transl. Med.* **10**, <https://doi.org/10.1126/scitranslmed.aao4755>
- 63 Jernberg, C., Löfmark, S., Edlund, C. and Jansson, J.K. (2007) Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. *ISME J.* **1**, 56–66, <https://doi.org/10.1038/ismej.2007.3>
- 64 Jakobsson, H.E., Jernberg, C., Andersson, A.F., Sjölund-Karlsson, M., Jansson, J.K. and Engstrand, L. (2010) Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. *PLoS ONE* **5**, e9836, <https://doi.org/10.1371/journal.pone.0009836>
- 65 Dethlefsen, L. and Relman, D.A. (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 4554–4561, <https://doi.org/10.1073/pnas.1000087107>
- 66 Isaac, S., Scher, J.U., Djukovic, A., Jiménez, N., Littman, D.R., Abramson, S.B. et al. (2017) Short- and long-term effects of oral vancomycin on the human intestinal microbiota. *J. Antimicrob. Chemother.* **72**, 128–136, <https://doi.org/10.1093/jac/dkw383>
- 67 Vrieze, A., Out, C., Fuentes, S., Jonker, L., Reuling, I., Kootte, R.S. et al. (2014) Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. *J. Hepatol.* **60**, 824–831, <https://doi.org/10.1016/j.jhep.2013.11.034>
- 68 Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A.R. et al. (2020) Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. *Nat. Commun.* **11**, 362, <https://doi.org/10.1038/s41467-019-14177-z>
- 69 Weersma, R.K., Zhernakova, A. and Fu, J. (2020) Interaction between drugs and the gut microbiome. *Gut* **69**, 1510–1519, <https://doi.org/10.1136/gutjnl-2019-320204>
- 70 Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N. et al. (2010) Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 11971–11975, <https://doi.org/10.1073/pnas.1002601107>
- 71 Mackie, R.I., Sghir, A. and Gaskins, H.R. (1999) Developmental microbial ecology of the neonatal gastrointestinal tract. *Am. J. Clin. Nutr.* **69**, 1035s–1045s, <https://doi.org/10.1093/ajcn/69.5.1035s>
- 72 Cahenzli, J., Koller, Y., Wyss, M., Geuking, M.B. and McCoy, K.D. (2013) Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. *Cell Host Microbe* **14**, 559–570, <https://doi.org/10.1016/j.chom.2013.10.004>
- 73 Jakobsson, H.E., Abrahamsson, T.R., Jenmalm, M.C., Harris, K., Quince, C., Jernberg, C. et al. (2014) Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section. *Gut* **63**, 559–566, <https://doi.org/10.1136/gutjnl-2012-303249>
- 74 Stewart, C.J., Ajami, N.J., O'Brien, J.L., Hutchinson, D.S., Smith, D.P., Wong, M.C. et al. (2018) Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature* **562**, 583–588, <https://doi.org/10.1038/s41586-018-0617-x>
- 75 Agans, R., Rigsbee, L., Kenche, H., Michail, S., Khamis, H.J. and Paliy, O. (2011) Distal gut microbiota of adolescent children is different from that of adults. *FEMS Microbiol. Ecol.* **77**, 404–412, <https://doi.org/10.1111/j.1574-6941.2011.01120.x>
- 76 Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J.H., Chinwalla, A.T. et al. (2012) Structure, function and diversity of the healthy human microbiome. *Nature* **486**, 207, <https://doi.org/10.1038/nature11234>
- 77 Quigley, E.M. (2013) Gut bacteria in health and disease. *Gastroenterol. Hepatol. (N.Y.)* **9**, 560
- 78 Odamaki, T., Kato, K., Sugahara, H., Hashikura, N., Takahashi, S., Xiao, J.-Z. et al. (2016) Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol.* **16**, 1–12, <https://doi.org/10.1186/s12866-016-0708-5>
- 79 Ragonnaud, E. and Biragyn, A. (2021) Gut microbiota as the key controllers of “healthy” aging of elderly people. *Immun. Ageing* **18**, 2, <https://doi.org/10.1186/s12979-020-00213-w>
- 80 De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J.B., Massart, S. et al. (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 14691–14696, <https://doi.org/10.1073/pnas.1005963107>
- 81 Grzeskowiak, L., Collado, M.C., Mangani, C., Maleta, K., Laitinen, K., Ashorn, P. et al. (2012) Distinct gut microbiota in southeastern African and northern European infants. *J. Pediatr. Gastroenterol. Nutr.* **54**, 812–816, <https://doi.org/10.1097/MPG.0b013e318249039c>
- 82 Gomez, A., Petrzalkova Klara, J., Burns Michael, B., Yeoman Carl, J., Amato Katherine, R., Vlckova, K. et al. (2016) Gut microbiome of coexisting BaAka pygmies and Bantu reflects gradients of traditional subsistence patterns. *Cell Rep.* **14**, 2142–2153, <https://doi.org/10.1016/j.celrep.2016.02.013>
- 83 Morton, E.R., Lynch, J., Froment, A., Lafosse, S., Heyer, E., Przeworski, M. et al. (2015) Variation in rural African gut microbiota is strongly correlated with colonization by Entamoeba and subsistence. *PLoS Genet.* **11**, e1005658, <https://doi.org/10.1371/journal.pgen.1005658>
- 84 Greenhill, A.R., Tsuji, H., Ogata, K., Natsuhara, K., Morita, A., Soli, K. et al. (2015) Characterization of the gut microbiota of Papua New Guineans using reverse transcription quantitative PCR. *PLoS ONE* **10**, e0117427, <https://doi.org/10.1371/journal.pone.0117427>
- 85 Obregon-Tito, A.J., Tito, R.Y., Metcalf, J., Sankaranarayanan, K., Clemente, J.C., Ursell, L.K. et al. (2015) Subsistence strategies in traditional societies distinguish gut microbiomes. *Nat. Commun.* **6**, 6505, <https://doi.org/10.1038/ncomms7505>
- 86 Schnorr, S.L., Candela, M., Rampelli, S., Centanni, M., Consolandi, C., Basaglia, G. et al. (2014) Gut microbiome of the Hadza hunter-gatherers. *Nat. Commun.* **5**, 3654, <https://doi.org/10.1038/ncomms4654>
- 87 Shreiner, A., Huffnagle, G.B. and Noverr, M.C. (2008) The “Microflora Hypothesis” of allergic disease. *Adv. Exp. Med. Biol.* **635**, 113–134, [https://doi.org/10.1007/978-0-387-09550-9\\_10](https://doi.org/10.1007/978-0-387-09550-9_10)
- 88 Jha, A.R., Davenport, E.R., Gautam, Y., Bhandari, D., Tandukar, S., Ng, K.M. et al. (2018) Gut microbiome transition across a lifestyle gradient in Himalaya. *PLoS Biol.* **16**, e2005396, <https://doi.org/10.1371/journal.pbio.2005396>
- 89 Martino, D. (2019) The effects of chlorinated drinking water on the assembly of the intestinal microbiome. *Challenges* **10**, 10, <https://doi.org/10.3390/challe10010010>



- 90 Mowat, A.M. (2018) To respond or not to respond - a personal perspective of intestinal tolerance. *Nat. Rev. Immunol.* **18**, 405–415, <https://doi.org/10.1038/s41577-018-0002-x>
- 91 Ohland, C.L. and Jobin, C. (2015) Microbial activities and intestinal homeostasis: a delicate balance between health and disease. *Cell Mol. Gastroenterol. Hepatol.* **1**, 28–40, <https://doi.org/10.1016/j.jcmgh.2014.11.004>
- 92 Chu, H. and Mazmanian, S.K. (2013) Innate immune recognition of the microbiota promotes host-microbial symbiosis. *Nat. Immunol.* **14**, 668–675, <https://doi.org/10.1038/ni.2635>
- 93 Takeuchi, O. and Akira, S. (2010) Pattern recognition receptors and inflammation. *Cell* **140**, 805–820, <https://doi.org/10.1016/j.cell.2010.01.022>
- 94 Fukata, M. and Arditi, M. (2013) The role of pattern recognition receptors in intestinal inflammation. *Mucosal Immunol.* **6**, 451–463, <https://doi.org/10.1038/mi.2013.13>
- 95 Rakoff-Nahoum, S., Pagliano, J., Eslami-Varzaneh, F., Edberg, S. and Medzhitov, R. (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell* **118**, 229–241, <https://doi.org/10.1016/j.cell.2004.07.002>
- 96 Erturk-Hasdemir, D., Oh, S.F., Okan, N.A., Stefanetti, G., Gazzaniga, F.S., Seeberger, P.H. et al. (2019) Symbionts exploit complex signaling to educate the immune system. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 26157–26166, <https://doi.org/10.1073/pnas.1915978116>
- 97 Nigro, G., Rossi, R., Commere, P.H., Jay, P. and Sansonetti, P.J. (2014) The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. *Cell Host Microbe* **15**, 792–798, <https://doi.org/10.1016/j.chom.2014.05.003>
- 98 Krautkramer, K.A., Fan, J. and Backhed, F. (2021) Gut microbial metabolites as multi-kingdom intermediates. *Nat. Rev. Microbiol.* **19**, 77–94, <https://doi.org/10.1038/s41579-020-0438-4>
- 99 Okumura, R. and Takeda, K. (2018) Maintenance of intestinal homeostasis by mucosal barriers. *Inflamm. Regen.* **38**, 5, <https://doi.org/10.1186/s41232-018-0063-z>
- 100 Pickard, J.M., Zeng, M.Y., Caruso, R. and Nunez, G. (2017) Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. *Immunol. Rev.* **279**, 70–89, <https://doi.org/10.1111/imr.12567>
- 101 Zong, X., Fu, J., Xu, B., Wang, Y. and Jin, M. (2020) Interplay between gut microbiota and antimicrobial peptides. *Anim. Nutr.* **6**, 389–396, <https://doi.org/10.1016/j.aninu.2020.09.002>
- 102 Lee, B., Moon, K.M. and Kim, C.Y. (2018) Tight junction in the intestinal epithelium: its association with diseases and regulation by phytochemicals. *J. Immunol. Res.* **2018**, 2645465, <https://doi.org/10.1155/2018/2645465>
- 103 Bansil, R. and Turner, B.S. (2018) The biology of mucus: composition, synthesis and organization. *Adv. Drug Deliv. Rev.* **124**, 3–15, <https://doi.org/10.1016/j.addr.2017.09.023>
- 104 Paone, P. and Cani, P.D. (2020) Mucus barrier, mucins and gut microbiota: the expected slimy partners? *Gut* **69**, 2232–2243, <https://doi.org/10.1136/gutjnl-2020-322260>
- 105 Johansson, M.E., Larsson, J.M. and Hansson, G.C. (2011) The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 4659–4665, <https://doi.org/10.1073/pnas.1006451107>
- 106 Lueschow, S.R. and McElroy, S.J. (2020) The Paneth cell: the curator and defender of the immature small intestine. *Front. Immunol.* **11**, 587, <https://doi.org/10.3389/fimmu.2020.00587>
- 107 Hilchie, A.L., Wuerth, K. and Hancock, R.E. (2013) Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. *Nat. Chem. Biol.* **9**, 761–768, <https://doi.org/10.1038/nchembio.1393>
- 108 Mansour, S.C., Pena, O.M. and Hancock, R.E. (2014) Host defense peptides: front-line immunomodulators. *Trends Immunol.* **35**, 443–450, <https://doi.org/10.1016/j.it.2014.07.004>
- 109 Tai, E.K., Wong, H.P., Lam, E.K., Wu, W.K., Yu, L., Koo, M.W. et al. (2008) Cathelicidin stimulates colonic mucus synthesis by up-regulating MUC1 and MUC2 expression through a mitogen-activated protein kinase pathway. *J. Cell. Biochem.* **104**, 251–258, <https://doi.org/10.1002/jcb.21615>
- 110 Robinson, K., Deng, Z., Hou, Y. and Zhang, G. (2015) Regulation of the intestinal barrier function by host defense peptides. *Front. Vet. Sci.* **2**, 57, <https://doi.org/10.3389/fvets.2015.00057>
- 111 Schroeder, B.O. (2019) Fight them or feed them: how the intestinal mucus layer manages the gut microbiota. *Gastroenterol. Rep.* **7**, 3–12, <https://doi.org/10.1093/gastro/goy052>
- 112 Bansal, T., Alaniz, R.C., Wood, T.K. and Jayaraman, A. (2010) The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 228–233, <https://doi.org/10.1073/pnas.0906112107>
- 113 Shimada, Y., Kinoshita, M., Harada, K., Mizutani, M., Masahata, K., Kayama, H. et al. (2013) Commensal bacteria-dependent indole production enhances epithelial barrier function in the colon. *PLoS ONE* **8**, e80604, <https://doi.org/10.1371/journal.pone.0080604>
- 114 Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A.P. et al. (2014) Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. *Immunity* **41**, 296–310, <https://doi.org/10.1016/j.immuni.2014.06.014>
- 115 Singh, R., Chandrashekarappa, S., Bodduluri, S.R., Baby, B.V., Hegde, B., Kotla, N.G. et al. (2019) Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. *Nat. Commun.* **10**, 89, <https://doi.org/10.1038/s41467-018-07859-7>
- 116 Roediger, W.E. (1980) Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. *Gut* **21**, 793–798, <https://doi.org/10.1136/gut.21.9.793>
- 117 Parada Venegas, D., De La Fuente, M.K., Landskron, G., Gonzalez, M.J., Quera, R., Dijkstra, G. et al. (2019) Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Front. Immunol.* **10**, 277, <https://doi.org/10.3389/fimmu.2019.00277>
- 118 Kelly, C.J., Zheng, L., Campbell, E.L., Saeedi, B., Scholz, C.C., Bayless, A.J. et al. (2015) Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. *Cell Host Microbe* **17**, 662–671, <https://doi.org/10.1016/j.chom.2015.03.005>

- 119 Nepelska, M., de Wouters, T., Jacouton, E., Beguet-Crespel, F., Lapaque, N., Dore, J. et al. (2017) Commensal gut bacteria modulate phosphorylation-dependent PPAR $\gamma$  transcriptional activity in human intestinal epithelial cells. *Sci. Rep.* **7**, 43199, <https://doi.org/10.1038/srep43199>
- 120 Ritzhaupt, A., Wood, I.S., Ellis, A., Hosie, K.B. and Shirazi-Beechey, S.P. (1998) Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. *J. Physiol.* **513**, 719–732, <https://doi.org/10.1111/j.1469-7793.1998.719ba.x>
- 121 Sivaprakasam, S., Bhutia, Y.D., Yang, S. and Ganapathy, V. (2017) Short-chain fatty acid transporters: role in colonic homeostasis. *Compr. Physiol.* **8**, 299–314, <https://doi.org/10.1002/cphy.c170014>
- 122 Alex, S., Lange, K., Amolo, T., Grinstead, J.S., Haakonsson, A.K., Szalowska, E. et al. (2013) Short-chain fatty acids stimulate angiotensin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor gamma. *Mol. Cell. Biol.* **33**, 1303–1316, <https://doi.org/10.1128/MCB.00858-12>
- 123 Sivaprakasam, S., Prasad, P.D. and Singh, N. (2016) Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. *Pharmacol. Ther.* **164**, 144–151, <https://doi.org/10.1016/j.pharmthera.2016.04.007>
- 124 Macia, L., Tan, J., Vieira, A.T., Leach, K., Stanley, D., Luong, S. et al. (2015) Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. *Nat. Commun.* **6**, 6734, <https://doi.org/10.1038/ncomms7734>
- 125 Brown, A.J., Goldsworthy, S.M., Barnes, A.A., Eilert, M.M., Tcheang, L., Daniels, D. et al. (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J. Biol. Chem.* **278**, 11312–11319, <https://doi.org/10.1074/jbc.M211609200>
- 126 Chen, B., Chen, H., Shu, X., Yin, Y., Li, J., Qin, J. et al. (2018) Presence of segmented filamentous bacteria in human children and its potential role in the modulation of human gut immunity. *Front. Microbiol.* **9**, 1403, <https://doi.org/10.3389/fmicb.2018.01403>
- 127 Burger-van Paassen, N., Vincent, A., Puiman, P.J., van der Sluis, M., Bouma, J., Boehm, G. et al. (2009) The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. *Biochem. J.* **420**, 211–219, <https://doi.org/10.1042/BJ20082222>
- 128 Zhao, Y., Chen, F., Wu, W., Sun, M., Bilotta, A.J., Yao, S. et al. (2018) GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. *Mucosal Immunol.* **11**, 752–762, <https://doi.org/10.1038/mi.2017.118>
- 129 Miyamoto, J., Mizukure, T., Park, S.B., Kishino, S., Kimura, I., Hirano, K. et al. (2015) A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. *J. Biol. Chem.* **290**, 2902–2918, <https://doi.org/10.1074/jbc.M114.610733>
- 130 Yao, B., He, J., Yin, X., Shi, Y., Wan, J. and Tian, Z. (2019) The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF- $\kappa$ B dependent mechanism in Caco-2 cells. *Toxicol. Lett.* **316**, 109–118, <https://doi.org/10.1016/j.toxlet.2019.08.024>
- 131 Gensollen, T., Iyer, S.S., Kasper, D.L. and Blumberg, R.S. (2016) How colonization by microbiota in early life shapes the immune system. *Science* **352**, 539–544, <https://doi.org/10.1126/science.aad9378>
- 132 Bauer, H., Horowitz, R.E., Levenson, S.M. and Popper, H. (1963) The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. *Am. J. Pathol.* **42**, 471–483
- 133 Umetsaki, Y., Setoyama, H., Matsumoto, S. and Okada, Y. (1993) Expansion of alpha beta T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. *Immunology* **79**, 32–37
- 134 Hapfelmeier, S., Lawson, M.A., Slack, E., Kirundi, J.K., Stoel, M., Heikenwalder, M. et al. (2010) Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. *Science* **328**, 1705–1709, <https://doi.org/10.1126/science.1188454>
- 135 Gomez de Agüero, M., Ganai-Vonarburg, S.C., Fuhrer, T., Rupp, S., Uchimura, Y., Li, H. et al. (2016) The maternal microbiota drives early postnatal innate immune development. *Science* **351**, 1296–1302, <https://doi.org/10.1126/science.aad2571>
- 136 Ivanov, I.I., Frutos Rde, L., Manel, N., Yoshinaga, K., Rifkin, D.B., Sartor, R.B. et al. (2008) Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. *Cell Host Microbe* **4**, 337–349, <https://doi.org/10.1016/j.chom.2008.09.009>
- 137 Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U. et al. (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* **139**, 485–498, <https://doi.org/10.1016/j.cell.2009.09.033>
- 138 Tan, T.G., Sefik, E., Geva-Zatorsky, N., Kua, L., Naskar, D., Teng, F. et al. (2016) Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E8141–E8150, <https://doi.org/10.1073/pnas.1617460113>
- 139 Atarashi, K., Tanoue, T., Ando, M., Kamada, N., Nagano, Y., Narushima, S. et al. (2015) Th17 cell induction by adhesion of microbes to intestinal epithelial cells. *Cell* **163**, 367–380, <https://doi.org/10.1016/j.cell.2015.08.058>
- 140 Mazmanian, S.K., Liu, C.H., Tzianabos, A.O. and Kasper, D.L. (2005) An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell* **122**, 107–118, <https://doi.org/10.1016/j.cell.2005.05.007>
- 141 An, D., Oh, S.F., Olszak, T., Neves, J.F., Avci, F.Y., Erturk-Hasdemir, D. et al. (2014) Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. *Cell* **156**, 123–133, <https://doi.org/10.1016/j.cell.2013.11.042>
- 142 Wesemann, D.R., Portuguese, A.J., Meyers, R.M., Gallagher, M.P., Cluff-Jones, K., Magee, J.M. et al. (2013) Microbial colonization influences early B-lineage development in the gut lamina propria. *Nature* **501**, 112–115, <https://doi.org/10.1038/nature12496>
- 143 Levy, M., Thaiss, C.A., Zeevi, D., Dohnalova, L., Zilberman-Schapira, G., Mahdi, J.A. et al. (2015) Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. *Cell* **163**, 1428–1443, <https://doi.org/10.1016/j.cell.2015.10.048>
- 144 Seo, S.U., Kamada, N., Munoz-Planillo, R., Kim, Y.G., Kim, D., Koizumi, Y. et al. (2015) Distinct commensals induce interleukin-1 $\beta$  via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. *Immunity* **42**, 744–755, <https://doi.org/10.1016/j.immuni.2015.03.004>

- 145 Wolf, A.J. and Underhill, D.M. (2018) Peptidoglycan recognition by the innate immune system. *Nat. Rev. Immunol.* **18**, 243–254, <https://doi.org/10.1038/nri.2017.136>
- 146 Bain, C.C., Bravo-Blas, A., Scott, C.L., Perdiguero, E.G., Geissmann, F., Henri, S. et al. (2014) Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat. Immunol.* **15**, 929–937, <https://doi.org/10.1038/ni.2967>
- 147 Danne, C., Ryzhakov, G., Martinez-Lopez, M., Iliot, N.E., Franchini, F., Cuskin, F. et al. (2017) A large polysaccharide produced by *Helicobacter hepaticus* induces an anti-inflammatory gene signature in macrophages. *Cell Host Microbe* **22**, 733.e5–745.e5, <https://doi.org/10.1016/j.chom.2017.11.002>
- 148 Schulthess, J., Pandey, S., Capitani, M., Rue-Albrecht, K.C., Arnold, I., Franchini, F. et al. (2019) The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. *Immunity* **50**, 432.e7–445.e7, <https://doi.org/10.1016/j.immuni.2018.12.018>
- 149 Wu, K., Yuan, Y., Yu, H., Dai, X., Wang, S., Sun, Z. et al. (2020) The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. *Blood* **136**, 501–515, <https://doi.org/10.1182/blood.2019003990>
- 150 Yue, C., Yang, X., Li, J., Chen, X., Zhao, X., Chen, Y. et al. (2017) Trimethylamine N-oxide prime NLRP3 inflammasome via inhibiting ATG16L1-induced autophagy in colonic epithelial cells. *Biochem. Biophys. Res. Commun.* **490**, 541–551, <https://doi.org/10.1016/j.bbrc.2017.06.075>
- 151 Sonnenberg, G.F. and Artis, D. (2015) Innate lymphoid cells in the initiation, regulation and resolution of inflammation. *Nat. Med.* **21**, 698–708, <https://doi.org/10.1038/nm.3892>
- 152 Ganai-Vonarburg, S.C. and Duerr, C.U. (2020) The interaction of intestinal microbiota and innate lymphoid cells in health and disease throughout life. *Immunology* **159**, 39–51, <https://doi.org/10.1111/imm.13138>
- 153 Gury-BenAri, M., Thaiss, C.A., Serafini, N., Winter, D.R., Giladi, A., Lara-Astiaso, D. et al. (2016) The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome. *Cell* **166**, 1231.e13–1246.e13, <https://doi.org/10.1016/j.cell.2016.07.043>
- 154 Chun, E., Lavoie, S., Fonseca-Pereira, D., Bae, S., Michaud, M., Hoveyda, H.R. et al. (2019) Metabolite-sensing receptor Ffar2 regulates colonic group 3 innate lymphoid cells and gut immunity. *Immunity* **51**, 871.e6–884.e6, <https://doi.org/10.1016/j.immuni.2019.09.014>
- 155 Keir, M., Yi, Y., Lu, T. and Ghilardi, N. (2020) The role of IL-22 in intestinal health and disease. *J. Exp. Med.* **217**, e20192195, <https://doi.org/10.1084/jem.20192195>
- 156 Bostick, J.W., Wang, Y., Shen, Z., Ge, Y., Brown, J., Chen, Z.E. et al. (2019) Dichotomous regulation of group 3 innate lymphoid cells by nongastric *Helicobacter* species. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 24760–24769, <https://doi.org/10.1073/pnas.1908128116>
- 157 Round, J.L. and Mazmanian, S.K. (2010) Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 12204–12209, <https://doi.org/10.1073/pnas.0909122107>
- 158 Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veecken, J., Deroos, P. et al. (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* **504**, 451–455, <https://doi.org/10.1038/nature12726>
- 159 Song, X., Sun, X., Oh, S.F., Wu, M., Zhang, Y., Zheng, W. et al. (2020) Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. *Nature* **577**, 410–415, <https://doi.org/10.1038/s41586-019-1865-0>
- 160 Zelante, T., Iannitti, R.G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G. et al. (2013) Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* **39**, 372–385, <https://doi.org/10.1016/j.immuni.2013.08.003>
- 161 Yoshii, K., Hosomi, K., Sawane, K. and Kunisawa, J. (2019) Metabolism of dietary and microbial vitamin B family in the regulation of host immunity. *Front. Nutr.* **6**, 48, <https://doi.org/10.3389/fnut.2019.00048>
- 162 Kunisawa, J., Sugiyama, Y., Wake, T., Nagatake, T., Suzuki, H., Nagasawa, R. et al. (2015) Mode of Bioenergetic metabolism during B cell differentiation in the intestine determines the distinct requirement for vitamin B1. *Cell Rep.* **13**, 122–131, <https://doi.org/10.1016/j.celrep.2015.08.063>
- 163 Schramm, M., Wiegmann, K., Schramm, S., Gluschko, A., Herb, M., Utermohlen, O. et al. (2014) Riboflavin (vitamin B2) deficiency impairs NADPH oxidase 2 (Nox2) priming and defense against *Listeria monocytogenes*. *Eur. J. Immunol.* **44**, 728–741, <https://doi.org/10.1002/eji.201343940>
- 164 Kjer-Nielsen, L., Patel, O., Corbett, A.J., Le Nours, J., Meehan, B., Liu, L. et al. (2012) MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* **491**, 717–723, <https://doi.org/10.1038/nature11605>
- 165 Eckle, S.B., Birkinshaw, R.W., Kostenko, L., Corbett, A.J., McWilliam, H.E., Reantragoon, R. et al. (2014) A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. *J. Exp. Med.* **211**, 1585–1600, <https://doi.org/10.1084/jem.20140484>
- 166 Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H. et al. (2014) Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity* **40**, 128–139, <https://doi.org/10.1016/j.immuni.2013.12.007>
- 167 Agrawal, S., Agrawal, A. and Said, H.M. (2016) Biotin deficiency enhances the inflammatory response of human dendritic cells. *Am. J. Physiol. Cell Physiol.* **311**, C386–C391, <https://doi.org/10.1152/ajpcell.00141.2016>
- 168 Skupsky, J., Sabui, S., Hwang, M., Nakasaki, M., Cahalan, M.D. and Said, H.M. (2020) Biotin supplementation ameliorates murine colitis by preventing NF-kappaB activation. *Cell Mol. Gastroenterol. Hepatol.* **9**, 557–567, <https://doi.org/10.1016/j.jcmgh.2019.11.011>
- 169 Tamura, J., Kubota, K., Murakami, H., Sawamura, M., Matsushima, T., Tamura, T. et al. (1999) Immunomodulation by vitamin B12: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. *Clin. Exp. Immunol.* **116**, 28–32, <https://doi.org/10.1046/j.1365-2249.1999.00870.x>
- 170 Lee, Y.K. and Mazmanian, S.K. (2010) Has the microbiota played a critical role in the evolution of the adaptive immune system? *Science* **330**, 1768–1773, <https://doi.org/10.1126/science.1195568>
- 171 Harmsen, H.J. and de Goffau, M.C. (2016) The human gut microbiota. *Microbiota Human Body* **902**, 95–108, [https://doi.org/10.1007/978-3-319-31248-4\\_7](https://doi.org/10.1007/978-3-319-31248-4_7)
- 172 DeGruttola, A.K., Low, D., Mizoguchi, A. and Mizoguchi, E. (2016) Current understanding of dysbiosis in disease in human and animal models. *Inflamm. Bowel Dis.* **22**, 1137–1150, <https://doi.org/10.1097/MIB.0000000000000750>
- 173 Belkaid, Y. and Hand, T.W. (2014) Role of the microbiota in immunity and inflammation. *Cell* **157**, 121–141, <https://doi.org/10.1016/j.cell.2014.03.011>

- 174 Das, B. and Nair, G.B. (2019) Homeostasis and dysbiosis of the gut microbiome in health and disease. *J. Biosci.* **44**, 1–8, <https://doi.org/10.1007/s12038-019-9926-y>
- 175 Nguyen, T.L.A., Vieira-Silva, S., Liston, A. and Raes, J. (2015) How informative is the mouse for human gut microbiota research? *Dis. Model Mech.* **8**, 1–16, <https://doi.org/10.1242/dmm.017400>
- 176 Mulder, D.J., Noble, A.J., Justinich, C.J. and Duffin, J.M. (2014) A tale of two diseases: the history of inflammatory bowel disease. *J. Crohns Colitis* **8**, 341–348, <https://doi.org/10.1016/j.crohns.2013.09.009>
- 177 Pascal, V., Pozuelo, M., Borrueal, N., Casellas, F., Campos, D., Santiago, A. et al. (2017) A microbial signature for Crohn's disease. *Gut* **66**, 813–822, <https://doi.org/10.1136/gutjnl-2016-313235>
- 178 Gevers, D., Kugathasan, S., Denson Lee, A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B. et al. (2014) The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host Microbe* **15**, 382–392, <https://doi.org/10.1016/j.chom.2014.02.005>
- 179 Martínez-Medina, M., Aldeguer, X., Lopez-Siles, M., González-Huix, F., López-Oliu, C., Dahbi, G. et al. (2009) Molecular diversity of *Escherichia coli* in the human gut: new ecological evidence supporting the role of adherent-invasive *E. coli* (AIEC) in Crohn's disease. *Inflamm. Bowel Dis.* **15**, 872–882, <https://doi.org/10.1002/ibd.20860>
- 180 Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C. et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* **464**, 59–65, <https://doi.org/10.1038/nature08821>
- 181 Willing, B., Halfvarson, J., Dicksved, J., Rosenquist, M., Järnerot, G., Engstrand, L. et al. (2009) Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. *Inflamm. Bowel Dis.* **15**, 653–660, <https://doi.org/10.1002/ibd.20783>
- 182 Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L.G., Gratadoux, J.-J. et al. (2008) *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 16731–16736, <https://doi.org/10.1073/pnas.0804812105>
- 183 Loubinoux, J., Bronowicki, J.-P., Pereira, I.A.C., Mouguel, J.-L. and Le Faou, A.E. (2002) Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. *FEMS Microbiol. Ecol.* **40**, 107–112, <https://doi.org/10.1111/j.1574-6941.2002.tb00942.x>
- 184 Jia, W., Whitehead, R.N., Griffiths, L., Dawson, C., Bai, H., Waring, R.H. et al. (2012) Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease. *FEMS Immunol. Med. Microbiol.* **65**, 55–68, <https://doi.org/10.1111/j.1574-695X.2012.00935.x>
- 185 Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.L., Barnich, N. et al. (2004) High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. *Gastroenterology* **127**, 412–421, <https://doi.org/10.1053/j.gastro.2004.04.061>
- 186 Palmela, C., Chevarin, C., Xu, Z., Torres, J., Sevrin, G., Hirten, R. et al. (2018) Adherent-invasive *Escherichia coli* in inflammatory bowel disease. *Gut* **67**, 574–587, <https://doi.org/10.1136/gutjnl-2017-314903>
- 187 Nikolaus, S., Schulte, B., Al-Massad, N., Thieme, F., Schulte, D.M., Bethge, J. et al. (2017) Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases. *Gastroenterology* **153**, 1504.e2–1516.e2, <https://doi.org/10.1053/j.gastro.2017.08.028>
- 188 Lamas, B., Richard, M.L., Leducq, V., Pham, H.-P., Michel, M.-L., Da Costa, G. et al. (2016) CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. *Nat. Med.* **22**, 598–605, <https://doi.org/10.1038/nm.4102>
- 189 Singh, P., Arora, A., Strand, T.A., Leffler, D.A., Catassi, C., Green, P.H. et al. (2018) Global prevalence of celiac disease: systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* **16**, 823.e2–836.e2, <https://doi.org/10.1016/j.cgh.2017.06.037>
- 190 De Re, V., Magris, R. and Cannizzaro, R. (2017) New insights into the pathogenesis of Celiac disease. *Front. Med.* **4**, 137, <https://doi.org/10.3389/fmed.2017.00137>
- 191 Akobeng, A.K., Singh, P., Kumar, M. and Al Khodor, S. (2020) Role of the gut microbiota in the pathogenesis of coeliac disease and potential therapeutic implications. *Eur. J. Nutr.* **59**, 3369–3390, <https://doi.org/10.1007/s00394-020-02324-y>
- 192 Collado, M.C., Calabuig, M. and Sanz, Y. (2007) Differences between the fecal microbiota of coeliac infants and healthy controls. *Curr. Issues Intest. Microbiol.* **8**, 9–14
- 193 De Palma, G., Nadal, I., Medina, M., Donat, E., Ribes-Koninckx, C., Calabuig, M. et al. (2010) Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. *BMC Microbiol.* **10**, 63, <https://doi.org/10.1186/1471-2180-10-63>
- 194 Sanz, Y., Sánchez, E., Marzotto, M., Calabuig, M., Torriani, S. and Dellaglio, F. (2007) Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. *FEMS Immunol. Med. Microbiol.* **51**, 562–568, <https://doi.org/10.1111/j.1574-695X.2007.00337.x>
- 195 Sánchez, E., Laparra, J.M. and Sanz, Y. (2012) Discerning the role of *Bacteroides fragilis* in celiac disease pathogenesis. *Appl. Environ. Microbiol.* **78**, 6507–6515, <https://doi.org/10.1128/AEM.00563-12>
- 196 Shiba, T., Aiba, Y., Ishikawa, H., Ushiyama, A., Takagi, A., Mine, T. et al. (2003) The suppressive effect of bifidobacteria on *Bacteroides vulgatus*, a putative pathogenic microbe in inflammatory bowel disease. *Microbiol. Immunol.* **47**, 371–378, <https://doi.org/10.1111/j.1348-0421.2003.tb03368.x>
- 197 Caminero, A., Herrán, A.R., Nistal, E., Pérez-Andrés, J., Vaquero, L., Vivas, S. et al. (2014) Diversity of the cultivable human gut microbiome involved in gluten metabolism: isolation of microorganisms with potential interest for coeliac disease. *FEMS Microbiol. Ecol.* **88**, 309–319, <https://doi.org/10.1111/1574-6941.12295>
- 198 Olivares, M., Laparra, M. and Sanz, Y. (2011) Influence of *Bifidobacterium longum* CECT 7347 and gliadin peptides on intestinal epithelial cell proteome. *J. Agric. Food Chem.* **59**, 7666–7671, <https://doi.org/10.1021/jf201212m>
- 199 Lindfors, K., Juuti-Uusitalo, K., Stenman, S., Venäläinen, J., Mäki, M. et al. (2008) Live probiotic *Bifidobacterium lactis* bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. *Clin. Exp. Immunol.* **152**, 552–558, <https://doi.org/10.1111/j.1365-2249.2008.03635.x>
- 200 Medina, M., De Palma, G., Ribes-Koninckx, C., Calabuig, M. and Sanz, Y. (2008) *Bifidobacterium* strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. *J. Inflamm.* **5**, 19, <https://doi.org/10.1186/1476-9255-5-19>



- 201 Laparra, J.M., Olivares, M., Gallina, O. and Sanz, Y. (2012) Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model. *PLoS ONE* **7**, e30744, <https://doi.org/10.1371/journal.pone.0030744>
- 202 Chen, V.L. and Kasper, D.L. (2014) Interactions between the intestinal microbiota and innate lymphoid cells. *Gut Microbes* **5**, 129–140, <https://doi.org/10.4161/gmic.27289>
- 203 Moro, K. and Koyasu, S. (2015) Innate lymphoid cells, possible interaction with microbiota. *Semin. Immunopathol.* **37**, 27–37, <https://doi.org/10.1007/s00281-014-0470-4>
- 204 Hrnčir, T., Stepankova, R., Kozakova, H., Hudcovic, T. and Tlaskalova-Hogenova, H. (2008) Gut microbiota and lipopolysaccharide content of the diet influence development of regulatory T cells: studies in germ-free mice. *BMC Immunol.* **9**, 65, <https://doi.org/10.1186/1471-2172-9-65>
- 205 Silman, A.J. and Pearson, J.E. (2002) Epidemiology and genetics of rheumatoid arthritis. *Arthritis Res.* **4**, S265–S272, <https://doi.org/10.1186/ar578>
- 206 Chen, J., Wright, K., Davis, J.M., Jeraldo, P., Marietta, E.V., Murray, J. et al. (2016) An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. *Genome Med.* **8**, 43, <https://doi.org/10.1186/s13073-016-0299-7>
- 207 Liu, X., Zou, Q., Zeng, B., Fang, Y. and Wei, H. (2013) Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis. *Curr. Microbiol.* **67**, 170–176, <https://doi.org/10.1007/s00284-013-0338-1>
- 208 Maeda, Y., Kurakawa, T., Umemoto, E., Motooka, D., Ito, Y., Gotoh, K. et al. (2016) Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. *Arthritis Rheumatol.* **68**, 2646–2661, <https://doi.org/10.1002/art.39783>
- 209 Wu, H.-J., Ivanov, I.I., Darce, J., Hattori, K., Shima, T., Umesaki, Y. et al. (2010) Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* **32**, 815–827, <https://doi.org/10.1016/j.immuni.2010.06.001>
- 210 Wallin, M.T., Culpepper, W.J., Nichols, E., Bhutta, Z.A., Gebrehiwot, T.T., Hay, S.I. et al. (2019) Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **18**, 269–285, [https://doi.org/10.1016/S1474-4422\(18\)30443-5](https://doi.org/10.1016/S1474-4422(18)30443-5)
- 211 Chen, J., Chia, N., Kalari, K.R., Yao, J.Z., Novotna, M., Paz Soldan, M.M. et al. (2016) Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. *Sci. Rep.* **6**, 28484, <https://doi.org/10.1038/srep28484>
- 212 Cantarel, B.L., Waubant, E., Chehoud, C., Kuczynski, J., DeSantis, T.Z., Warrington, J. et al. (2015) Gut microbiota in multiple sclerosis: possible influence of immunomodulators. *J. Investig. Med.* **63**, 729–734, <https://doi.org/10.1097/JIM.0000000000000192>
- 213 Lee, Y.K., Menezes, J.S., Umesaki, Y. and Mazmanian, S.K. (2011) Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 4615–4622, <https://doi.org/10.1073/pnas.1000082107>
- 214 Nouri, M., Bredberg, A., Weström, B. and Lavasani, S. (2014) Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells. *PLoS ONE* **9**, e106335, <https://doi.org/10.1371/journal.pone.0106335>
- 215 Secher, T., Kassem, S., Benamar, M., Bernard, I., Boury, M., Barreau, F. et al. (2017) Oral administration of the probiotic strain Escherichia coli Nissle 1917 reduces susceptibility to neuroinflammation and repairs experimental autoimmune encephalomyelitis-induced intestinal barrier dysfunction. *Front. Immunol.* **8**, 1096, <https://doi.org/10.3389/fimmu.2017.01096>
- 216 Huang, P.L. (2009) A comprehensive definition for metabolic syndrome. *Dis. Model Mech.* **2**, 231–237, <https://doi.org/10.1242/dmm.001180>
- 217 Wang, P.-X., Deng, X.-R., Zhang, C.-H. and Yuan, H.-J. (2020) Gut microbiota and metabolic syndrome. *Chin. Med. J. (Engl.)* **133**, 808–816, <https://doi.org/10.1097/CM9.0000000000000696>
- 218 Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L. et al. (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science* **341**, 1241214, <https://doi.org/10.1126/science.1241214>
- 219 Bäckhed, F., Manchester, J.K., Semenkovich, C.F. and Gordon, J.I. (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 979–984, <https://doi.org/10.1073/pnas.0605374104>
- 220 Armougoum, F., Henry, M., Vialettes, B., Raccach, D. and Raoult, D. (2009) Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. *PLoS ONE* **4**, e7125, <https://doi.org/10.1371/journal.pone.0007125>
- 221 Koliada, A., Syzhenko, G., Moseiko, V., Budovska, L., Puchkov, K., Perederiy, V. et al. (2017) Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. *BMC Microbiol.* **17**, 120, <https://doi.org/10.1186/s12866-017-1027-1>
- 222 Kong, L.C., Tap, J., Aron-Wisniewsky, J., Pelloux, V., Basdevant, A., Bouillot, J.L. et al. (2013) Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. *Am. J. Clin. Nutr.* **98**, 16–24, <https://doi.org/10.3945/ajcn.113.058743>
- 223 Li, J.V., Ashrafian, H., Bueter, M., Kinross, J., Sands, C., le Roux, C.W. et al. (2011) Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. *Gut* **60**, 1214–1223, <https://doi.org/10.1136/gut.2010.234708>
- 224 Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F. et al. (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* **490**, 55–60, <https://doi.org/10.1038/nature11450>
- 225 Samuel, B.S., Shaito, A., Motoike, T., Rey, F.E., Backhed, F., Manchester, J.K. et al. (2008) Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 16767–16772, <https://doi.org/10.1073/pnas.0808567105>
- 226 Lin, H.V., Frassetto, A., Kowalik, Jr, E.J., Nawrocki, A.R., Lu, M.M., Kosinski, J.R. et al. (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS ONE* **7**, e35240, <https://doi.org/10.1371/journal.pone.0035240>
- 227 Cani, P.D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O. et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. *Gut* **58**, 1091–1103, <https://doi.org/10.1136/gut.2008.165886>
- 228 Chakaroun, R.M., Massier, L. and Kovacs, P. (2020) Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders? *Nutrients* **12**, 1082, <https://doi.org/10.3390/nu12041082>

- 229 Raso, G.M., Simeoli, R., Iacono, A., Santoro, A., Amero, P., Paciello, O. et al. (2014) Effects of a *Lactobacillus paracasei* B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. *J. Nutr. Biochem.* **25**, 81–90, <https://doi.org/10.1016/j.jnutbio.2013.09.006>
- 230 Martínez-Medina, M., Denizot, J., Dreux, N., Robin, F., Billard, E., Bonnet, R. et al. (2014) Western diet induces dysbiosis with increased *E. coli* in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. *Gut* **63**, 116–124, <https://doi.org/10.1136/gutjnl-2012-304119>
- 231 Wang, X., Ota, N., Manzanillo, P., Kates, L., Zavala-Solorio, J., Eidsenchenk, C. et al. (2014) Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. *Nature* **514**, 237–241, <https://doi.org/10.1038/nature13564>
- 232 Burcelin, R. (2016) Gut microbiota and immune crosstalk in metabolic disease. *Mol. Metab.* **5**, 771–781, <https://doi.org/10.1016/j.molmet.2016.05.016>
- 233 Su, G.L., Ko, C.W., Bercik, P., Falck-Ytter, Y., Sultan, S., Weizman, A.V. et al. (2020) AGA Clinical Practice Guidelines on the role of probiotics in the management of gastrointestinal disorders. *Gastroenterology* **159**, 697–705, <https://doi.org/10.1053/j.gastro.2020.05.059>
- 234 Mullish, B.H., Quraishi, M.N., Segal, J.P., McCune, V.L., Baxter, M., Marsden, G.L. et al. (2018) The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. *Gut* **67**, 1920–1941, <https://doi.org/10.1136/gutjnl-2018-316818>
- 235 Sanders, M.E., Merenstein, D.J., Reid, G., Gibson, G.R. and Rastall, R.A. (2019) Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat. Rev. Gastroenterol. Hepatol.* **16**, 605–616, <https://doi.org/10.1038/s41575-019-0173-3>
- 236 Segal, J.P., Mullish, B.H., Quraishi, M.N., Iqbal, T., Marchesi, J.R. and Sokol, H. (2020) Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. *Ther. Adv. Gastroenterol.* **13**, 1756284820946904, <https://doi.org/10.1177/1756284820946904>
- 237 Yan, F. and Polk, D.B. (2020) Probiotics and probiotic-derived functional factors—mechanistic insights into applications for intestinal homeostasis. *Front. Immunol.* **11**, 1428, <https://doi.org/10.3389/fimmu.2020.01428>
- 238 Mujagic, Z., de Vos, P., Boekschoten, M.V., Govers, C., Pieters, H.H., de Wit, N.J. et al. (2017) The effects of *Lactobacillus plantarum* on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial. *Sci. Rep.* **7**, 40128, <https://doi.org/10.1038/srep40128>
- 239 Schiavi, E., Gleinser, M., Molloy, E., Groeger, D., Frei, R., Ferstl, R. et al. (2016) The surface-associated exopolysaccharide of *Bifidobacterium longum* 35624 plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses. *Appl. Environ. Microbiol.* **82**, 7185–7196, <https://doi.org/10.1128/AEM.02238-16>
- 240 Alessandri, G., Ossiprandi, M.C., MacSharry, J., van Sinderen, D. and Ventura, M. (2019) Bifidobacterial dialogue with its human host and consequent modulation of the immune system. *Front. Immunol.* **10**, 2348, <https://doi.org/10.3389/fimmu.2019.02348>
- 241 Chelakkot, C., Choi, Y., Kim, D.K., Park, H.T., Ghim, J., Kwon, Y. et al. (2018) Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. *Exp. Mol. Med.* **50**, e450, <https://doi.org/10.1038/emm.2017.282>
- 242 Bäuerl, C., Coll-Marqués, J.M., Tarazona-González, C. and Pérez-Martínez, G. (2020) *Lactobacillus casei* extracellular vesicles stimulate EGFR pathway likely due to the presence of proteins P40 and P75 bound to their surface. *Sci. Rep.* **10**, 19237, <https://doi.org/10.1038/s41598-020-75930-9>
- 243 Hols, P., Ledesma-García, L., Gabant, P. and Mignolet, J. (2019) Mobilization of microbiota commensals and their bacteriocins for therapeutics. *Trends Microbiol.* **27**, 690–702, <https://doi.org/10.1016/j.tim.2019.03.007>
- 244 Rivière, A., Selak, M., Lantin, D., Leroy, F. and De Vuyst, L. (2016) Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. *Front. Microbiol.* **7**, 979, <https://doi.org/10.3389/fmicb.2016.00979>
- 245 Parker, E.A., Roy, T., D'Adamo, C.R. and Wieland, L.S. (2018) Probiotics and gastrointestinal conditions: an overview of evidence from the Cochrane Collaboration. *Nutrition* **45**, 125.e11–134.e11, <https://doi.org/10.1016/j.nut.2017.06.024>
- 246 Limketkai, B.N., Akobeng, A.K., Gordon, M. and Adepou, A.A. (2020) Probiotics for induction of remission in Crohn's disease. *Cochrane Database Syst. Rev.* **7**, CD006634
- 247 Kaur, L., Gordon, M., Baines, P.A., Iheozor-Ejiofor, Z., Sinopoulou, V. and Akobeng, A.K. (2020) Probiotics for induction of remission in ulcerative colitis. *Cochrane Database Syst. Rev.* **3**, CD005573
- 248 Iheozor-Ejiofor, Z., Kaur, L., Gordon, M., Baines, P.A., Sinopoulou, V. and Akobeng, A.K. (2020) Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database Syst. Rev.* **3**, CD007443
- 249 Ford, A.C., Harris, L.A., Lacy, B.E., Quigley, E.M.M. and Moayyedi, P. (2018) Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. *Aliment. Pharmacol. Ther.* **48**, 1044–1060, <https://doi.org/10.1111/apt.15001>
- 250 Goldenberg, J.Z., Yap, C., Lytvyn, L., Lo, C.K., Beardsley, J., Mertz, D. et al. (2017) Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. *Cochrane Database Syst. Rev.* **12**, CD006095, <https://doi.org/10.1002/14651858.CD006095.pub4>
- 251 Sniffen, J.C., McFarland, L.V., Evans, C.T. and Goldstein, E.J.C. (2018) Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. *PLoS ONE* **13**, e0209205, <https://doi.org/10.1371/journal.pone.0209205>
- 252 Ansari, J.M., Colasacco, C., Emmanouil, E., Kohlhepp, S. and Harriott, O. (2019) Strain-level diversity of commercial probiotic isolates of *Bacillus*, *Lactobacillus*, and *Saccharomyces* species illustrated by molecular identification and phenotypic profiling. *PLoS ONE* **14**, e0213841, <https://doi.org/10.1371/journal.pone.0213841>
- 253 Magnúsdóttir, S., Heinken, A., Kutt, L., Ravcheev, D.A., Bauer, E., Noronha, A. et al. (2017) Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. *Nat. Biotechnol.* **35**, 81–89, <https://doi.org/10.1038/nbt.3703>
- 254 Poyet, M., Groussin, M., Gibbons, S.M., Avila-Pacheco, J., Jiang, X., Kearney, S.M. et al. (2019) A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research. *Nat. Med.* **25**, 1442–1452, <https://doi.org/10.1038/s41591-019-0559-3>
- 255 Devika, N.T. and Raman, K. (2019) Deciphering the metabolic capabilities of Bifidobacteria using genome-scale metabolic models. *Sci. Rep.* **9**, 18222, <https://doi.org/10.1038/s41598-019-54696-9>

- 256 Yadav, M. and Shukla, P. (2019) Recent systems biology approaches for probiotics use in health aspects: a review. *3 Biotech* **9**, 448, <https://doi.org/10.1007/s13205-019-1980-5>
- 257 Tabashsum, Z., Peng, M., Salaheen, S., Comis, C. and Debabrata, B. (2017) Competitive elimination and virulence property alteration of *Campylobacter jejuni* by genetically engineered *Lactobacillus casei*. *Food Control* **85**, 283–291, <https://doi.org/10.1016/j.foodcont.2017.10.010>
- 258 Schellenberger, J.D., Que, R., Fleming, R.M.T., Thiele, I., Orth, J.D., Feist, A.M. et al. (2011) Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. *Nat. Protoc.* **6**, 1290–1307, <https://doi.org/10.1038/nprot.2011.308>
- 259 Ottman, N., Davids, M., Suarez-Diez, M., Boeren, S., Schaap, P.J., Martins Dos Santos, V.A.P. et al. (2017) Genome-scale model and omics analysis of metabolic capacities of *Akkermansia muciniphila* reveal a preferential mucin-degrading lifestyle. *Appl. Environ. Microbiol.* **83**, e01014–17, <https://doi.org/10.1128/AEM.01014-17>
- 260 Caputo, A., Dubourg, G., Croce, O., Gupta, S., Robert, C., Papazian, L. et al. (2015) Whole-genome assembly of *Akkermansia muciniphila* sequenced directly from human stool. *Biol. Direct* **10**, 5, <https://doi.org/10.1186/s13062-015-0041-1>
- 261 Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S. et al. (2018) Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. *Cell* **174**, 1388.e21–1405.e21, <https://doi.org/10.1016/j.cell.2018.08.041>
- 262 Kristensen, N.B., Bryrup, T., Allin, K.H., Nielsen, T., Hansen, T.H. and Pedersen, O. (2016) Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. *Genome Med.* **8**, 52, <https://doi.org/10.1186/s13073-016-0300-5>
- 263 Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B. et al. (2014) The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* **11**, 506–514, <https://doi.org/10.1038/nrgastro.2014.66>
- 264 Salminen, S., Collado, M.C., Endo, A., Hill, C., Lebeer, S., Quigley, E.M.M. et al. (2021) The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. *Nat. Rev. Gastroenterol. Hepatol.*, <https://doi.org/10.1038/s41575-021-00440-6>
- 265 Travers, M.-A., Sow, C., Zirah, S., Deregnacourt, C., Chaouch, S., Queiroz, R.M.L. et al. (2016) Deconjugated bile salts produced by extracellular bile-salt hydrolase-like activities from the probiotic *Lactobacillus johnsonii* La1 inhibit giardia duodenalis in vitro growth. *Front. Microbiol.* **7**, 1453, <https://doi.org/10.3389/fmicb.2016.01453>
- 266 Warda, A.K., de Almeida Bettio, P.H., Hueston, C.M., Di Benedetto, G., Clooney, A.G. and Hill, C. (2020) Oral administration of heat-treated lactobacilli modifies the murine microbiome and reduces citrobacter induced colitis. *Front. Microbiol.* **11**, 69, <https://doi.org/10.3389/fmicb.2020.00069>
- 267 Luceri, C., Femia, A.P., Fazi, M., Di Martino, C., Zolfanelli, F., Dolara, P. et al. (2016) Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: a randomized trial. *Dig. Liver Dis.* **48**, 27–33, <https://doi.org/10.1016/j.dld.2015.09.005>
- 268 Andresen, V., Gschossmann, J. and Layer, P. (2020) Heat-inactivated *Bifidobacterium bifidum* MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. *Lancet Gastroenterol. Hepatol.* **5**, 658–666, [https://doi.org/10.1016/S2468-1253\(20\)30056-X](https://doi.org/10.1016/S2468-1253(20)30056-X)
- 269 Cardinale, F., Lombardi, E., Rossi, O., Bagnasco, D., Bellocchi, A. and Menzella, F. (2020) Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. *Expert Rev. Respir. Med.* **14**, 1019–1026, <https://doi.org/10.1080/17476348.2020.1793673>
- 270 Yin, J., Xu, B., Zeng, X. and Shen, K. (2018) Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis. *Int. Immunopharmacol.* **54**, 198–209, <https://doi.org/10.1016/j.intimp.2017.10.032>
- 271 (EMA) EMA (2019) Bacterial lysates-containing medicinal products for respiratory conditions. *Assessment Rep.*, [https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-1/dir\\_2001\\_83\\_consol\\_2012/dir\\_2001\\_83\\_cons\\_2012\\_en.pdf](https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf)
- 272 Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H. et al. (2013) Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am. J. Gastroenterol.* **108**, 478–498, quiz 499, <https://doi.org/10.1038/ajg.2013.4>
- 273 Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R. et al. (2017) European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* **66**, 569–580, <https://doi.org/10.1136/gutjnl-2016-313017>
- 274 Quraishi, M.N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N. et al. (2017) Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory *Clostridium difficile* infection. *Aliment. Pharmacol. Ther.* **46**, 479–493, <https://doi.org/10.1111/apt.14201>
- 275 Fischer, M., Sipe, B., Cheng, Y.W., Phelps, E., Rogers, N., Sagi, S. et al. (2017) Fecal microbiota transplant in severe and severe-complicated *Clostridium difficile*: a promising treatment approach. *Gut Microbes* **8**, 289–302, <https://doi.org/10.1080/19490976.2016.1273998>
- 276 Dang, X., Xu, M., Liu, D., Zhou, D. and Yang, W. (2020) Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: a systematic review and meta-analysis. *PLoS ONE* **15**, e0228846, <https://doi.org/10.1371/journal.pone.0228846>
- 277 Zhao, H.L., Chen, S.Z., Xu, H.M., Zhou, Y.L., He, J., Huang, H.L. et al. (2020) Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: a systematic review and meta-analysis. *J. Digest. Dis.* **21**, 534–548, <https://doi.org/10.1111/1751-2980.12933>
- 278 Quraishi, M.N., Yalchin, M., Blackwell, C., Segal, J., Sharma, N., Hawkey, P. et al. (2019) STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis. *BMJ Open* **9**, e030659
- 279 Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U. et al. (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. *J. Crohns Colitis* **11**, 769–784, <https://doi.org/10.1093/ecco-jcc/jjx009>
- 280 Caldeira, L.F., Borba, H.H., Tonin, F.S., Wiens, A., Fernandez-Llimos, F. and Pontarolo, R. (2020) Fecal microbiota transplantation in inflammatory bowel disease patients: a systematic review and meta-analysis. *PLoS ONE* **15**, e0238910, <https://doi.org/10.1371/journal.pone.0238910>

- 281 Gomollón, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J.O. et al. (2017) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: diagnosis and medical management. *J. Crohns Colitis* **11**, 3–25, <https://doi.org/10.1093/ecco-jcc/jjw168>
- 282 Ianiro, G., Eusebi, L.H., Black, C.J., Gasbarrini, A., Cammarota, G. and Ford, A.C. (2019) Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. *Aliment. Pharmacol. Ther.* **50**, 240–248, <https://doi.org/10.1111/apt.15330>
- 283 Allegretti, J.R., Kassam, Z., Mullish, B.H., Chiang, A., Carrellas, M., Hurtado, J. et al. (2020) Effects of fecal microbiota transplantation with oral capsules in obese patients. *Clin. Gastroenterol. Hepatol.* **18**, 855.e2–863.e2, <https://doi.org/10.1016/j.cgh.2019.07.006>
- 284 Kootte, R.S., Levin, E., Salojärvi, J., Smits, L.P., Hartstra, A.V., Udayappan, S.D. et al. (2017) Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metab.* **26**, 611.e6–619.e6, <https://doi.org/10.1016/j.cmet.2017.09.008>
- 285 Bajaj, J.S., Salzman, N.H., Acharya, C., Sterling, R.K., White, M.B., Gavis, E.A. et al. (2019) Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. *Hepatology* **70**, 1690–1703, <https://doi.org/10.1002/hep.30690>
- 286 de Groot, P., Nikolic, T., Pellegrini, S., Sordi, V., Imangaliyev, S., Rampanelli, E. et al. (2021) Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. *Gut* **70**, 92–105, <https://doi.org/10.1136/gutjnl-2020-322630>
- 287 Vendrik, K.E.W., Ooijsvaar, R.E., de Jong, P.R.C., Laman, J.D., van Oosten, B.W., van Hilten, J.J. et al. (2020) Fecal microbiota transplantation in neurological disorders. *Front. Cell Infect. Microbiol.* **10**, 98, <https://doi.org/10.3389/fcimb.2020.00098>
- 288 Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M. et al. (2015) Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science* **350**, 1084–1089, <https://doi.org/10.1126/science.aac4255>
- 289 Vétizou, M., Pitt, J.M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C. et al. (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science* **350**, 1079–1084, <https://doi.org/10.1126/science.aad1329>
- 290 Davar, D., Dzutsev, A.K., McCulloch, J.A., Rodrigues, R.R., Chauvin, J.M., Morrison, R.M. et al. (2021) Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. *Science* **371**, 595–602, <https://doi.org/10.1126/science.abf3363>
- 291 Barr, J.J., Auro, R., Furlan, M., Whiteson, K.L., Erb, M.L., Pogliano, J. et al. (2013) Bacteriophage adhering to mucus provide a non-host-derived immunity. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 10771–10776, <https://doi.org/10.1073/pnas.1305923110>
- 292 Zuo, T., Wong, S.H., Lam, K., Lui, R., Cheung, K., Tang, W. et al. (2018) Bacteriophage transfer during faecal microbiota transplantation in *Clostridium difficile* infection is associated with treatment outcome. *Gut* **67**, 634–643
- 293 Zuo, T., Wong, S.H., Cheung, C.P., Lam, K., Lui, R., Cheung, K. et al. (2018) Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in *Clostridium difficile* infection. *Nat. Commun.* **9**, 3663, <https://doi.org/10.1038/s41467-018-06103-6>
- 294 Ott, S.J., Waetzig, G.H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J.A. et al. (2017) Efficacy of sterile fecal filtrate transfer for treating patients with *Clostridium difficile* infection. *Gastroenterology* **152**, 799.e7–811.e7, <https://doi.org/10.1053/j.gastro.2016.11.010>
- 295 Mabwi, H.A., Kim, E., Song, D.-G., Yoon, H.S., Pan, C.-H., Komba, E.V.G. et al. (2021) Synthetic gut microbiome: advances and challenges. *Comput. Struct. Biotechnol. J.* **19**, 363–371, <https://doi.org/10.1016/j.csbj.2020.12.029>
- 296 Petrof, E.O., Gloor, G.B., Vanner, S.J., Weese, S.J., Carter, D., Daigneault, M.C. et al. (2013) Stool substitute transplant therapy for the eradication of *Clostridium difficile* infection: 'RePOOPulating' the gut. *Microbiome* **1**, 3, <https://doi.org/10.1186/2049-2618-1-3>
- 297 Rode, A.A., Chehri, M., Krogsgaard, L.R., Heno, K.K., Svendsen, A.T., Ribberholt, I. et al. (2021) Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent *Clostridioides difficile* infections. *Aliment. Pharmacol. Ther.* **53**, 999–1009, <https://doi.org/10.1111/apt.16309>
- 298 Staley, C., Hamilton, M.J., Vaughn, B.P., Graiziger, C.T., Newman, K.M., Kabage, A.J. et al. (2017) Successful resolution of recurrent *Clostridium difficile* infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. *Am. J. Gastroenterol.* **112**, 940–947, <https://doi.org/10.1038/ajg.2017.6>